A Comparative Study of International Classification for

Lung Cancer and WHO Classification in Histological Diagnosis of Lung Cancer in Small Biopsies by Nithya, I
A  COMPARATIVE STUDY OF INTERNATIONAL CLASSIFICATION FOR 
LUNG CANCER AND WHO CLASSIFICATION IN HISTOLOGICAL 
DIAGNOSIS OF LUNG CANCER IN SMALL BIOPSIES 
Dissertation submitted in  
partial fulfilment of the requirements for the degree of 
M.D. (PATHOLOGY) 
BRANCH - III 
 
GOSCHEN INSTITUTE OF PATHOLOGY AND ELECTRON 
MICROSCOPY 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
 
 
 
THE TAMIL NADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
APRIL 2015 
 
 CERTIFICATE 
 This is to certify that this Dissertation entitled   “A  COMPARATIVE 
STUDY OF INTERNATIONAL CLASSIFICATION FOR LUNG CANCER AND 
WHO CLASSIFICATION IN HISTOLOGICAL DIAGNOSIS OF LUNG 
CANCER IN SMALL BIOPSIES” is the bonafide original work of Dr. NITHYA. I, 
in partial fulfillment of the requirement for M.D., (Branch III) in Pathology 
examination of the Tamilnadu Dr.M.G.R Medical University to be held in April 
2015. 
 
 
Prof. Dr RAMAMOORTHY, M.D.,            Prof. Dr. M.SARASWATHY, M.D.,                  
PROFESSOR OF PATHOLOGY,                    DIRECTOR & PROFESSOR,  
 Institute of pathology,                                   Institute of Pathology , 
Madras Medical College,               Madras Medical College 
Chennai – 600003.                   Chennai – 600003. 
 
 
 
 Prof. Dr. R.VIMALA, M.D., 
 DEAN, 
 Madras Medical College and  
 Government General Hospital, 
 Chennai - 600003 
 
 DECLARATION 
  I, Dr. Nithya .I, solemnly declare that the dissertation titled  
“A  COMPARATIVE STUDY OF INTERNATIONAL CLASSIFICATION FOR 
LUNG CANCER AND WHO CLASSIFICATION IN HISTOLOGICAL 
DIAGNOSIS OF LUNG CANCER IN SMALL BIOPSIES” is the bonafide work 
done by me at Institute of Pathology, Madras Medical College under the expert 
guidance and supervision of Prof. Dr. RAMAMOORTHY, M.D., Professor of 
Pathology,Institute of pathology, Madras Medical College. The dissertation is 
submitted to the Tamilnadu Dr. M.G.R Medical University towards partial 
fulfillment of requirement for the award of M.D., Degree (Branch III) in 
Pathology. 
 
 
Place:  Chennai 
Date:                             Dr. NITHYA.I 
 
  
ACKNOWLEDGEMENT 
 I express my sincere thanks to Prof. Dr.R.VIMALA , M.D., Dean, 
Madras Medical College and Government General Hospital, for permitting me 
to utilize the facilities of the Institution. 
 
 I take the opportunity to express my thanks to Prof.  
Dr.M.SARASWATHY, M.D., Director  and Professor, Institute of Pathology, 
Madras Medical College, Chennai for her keen interest, constant 
encouragement and valuable suggestions throughout the study. 
 
I am extremely thankful to Dr. RAMAMOORTHY, M.D., Professor 
of Pathology, Institute of pathology, Madras Medical College, for her valuable 
suggestions, constant support, advice and encouragements throughout the 
study. 
 
I am thankful to Prof. Dr. P.KARKUZHALI, M.D., Professor and 
former Director of Institute of Pathology, Madras Medical College for her      
initial  guidance  and  valuable  suggestions during  the  study. 
 
I am truly thankful to Prof. Dr. Shantha Ravisankar M.D.,  
Prof.Dr.Geetha Devadas M.D., D.C.P., Prof.Dr.Padmavathi M.D.,  
Prof.Dr.Kanchana M.D, Prof. Dr. Sudha Venkatesh M.D., Prof. Dr. K. 
Rama M.D., Prof.Dr.Rajavelu Indira Prof. Dr. S. Pappathi M.D., D.C.H., 
for their valuable suggestions and encouragement throughout the study. 
 
I express my heartfelt sincere thanks to all my Assistant Professors for 
their help and suggestions during the study. 
 
 I would  like to  thank  the Institutional  Ethics  Committee for 
approving  my study.   
 
           On a personal level, I extent my gratitude to my parents, my daughter 
B.SAHANA and all the members of the  family, with a special mention to 
Er.I.Mayilan, M.Tech and Er. N.Arunkumar, M.B.A., for their 
love,friendship,advice and support in my personal and professional endeavors. 
 
          I sincerely acknowledge the cooperation of my husband Dr.P.Baskaran 
,M.S.,Mch ,who ,as ,always ,has patiently guided me at every stage , offering 
me helpful criticisms and suggestions. 
 
        I thank my Friends, Colleagues, Senior Postgratuate, Junior Postgraduate, 
Technicians and the Staffs for their continuing support and helpful advice. 
 
I dedicated the entire thesis work to my late son, B.Siddharth, our 
bundle of joy, alive in our heart. He continues to live in this world, till our 
heartbeats.  
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
SCC  : Squamous cell carcinoma 
ADC       : Adenocarcinoma 
EGFR  : Epidermal growth factor receptor 
WHO  : World Health Organisation 
IASLC/ATS/ERS : International Association for the Study of Lung  
                                 Cancer/American Thoracic Society/European  
                                 Respiratory Society 
NSCLC       : Non Small Cell Lung Carcinoma 
NSCLC-NOS         : Non Small Cell Lung Carcinoma-not otherwise  
                                   specified 
TTF-1                 : Thyroid Transcription Factor-1 
AB/PAS                : Alcian Blue-Periodic Acid  Schiff Reagent 
IHC                   : Immunohistochemistry 
H & E                  : Hematoxylin & Eosin 
CIS                    : Carcinoma in situ 
BAC  :  Bronchoalveolar Carcinoma 
AIS  : Adenocarcinoma Insitu 
MIA  : Minimally Invasive Adenocarcinoma 
  
 CONTENTS 
S. NO. TITLE PAGE NUMBER 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 MATERIALS AND METHODS 47 
5 OBSERVATION AND RESULTS 52 
6 DISCUSSION 94 
7 SUMMARY 109 
8 CONCLUSION 112 
 
ANNEXURES 
BIBLIOGRAPHY 
 
 MASTER CHART  
 
 
 
 
A COMPARATIVE STUDY OF INTERNATIONAL CLASSIFICATION FOR 
LUNG CANCER AND WHO CLASSIFICATION IN HISTOLOGICAL 
DIAGNOSIS OF LUNG CANCER IN SMALL BIOPSIES 
 
ABSTRACT 
BACKGROUND : Lung cancer is a highly aggressive malignancy causing 
high morbidity and mortality. An increasing incidence of lung cancer has been 
observed in India. Currently, the classification of lung carcinoma has gone 
beyond small cell lung carcinoma and non‑small cell lung carcinoma (NSCLC). 
Precise subtyping of poorly differentiated NSCLC into adenocarcinoma and 
squamous cell carcinoma has a direct impact on patient management and 
prognosis.70% of lung cancers are unresectable, as patients present in advanced 
stages. Hence small biopsy and cytology specimens are the primary method of 
diagnosis for the majority of lung cancers.Also, prior 2004WHO classifications 
primarily addressed resection specimens, they did not propose standardized 
terminology and criteria for small biopsies and cytology. Hence this  new 2011 
IASLC classification provides for the first time a proposed set of terms and 
criteria for all major histologic types of lung cancer in small biopsies and 
cytology.   
 
AIMS AND OBJECTIVES: To classify lung cancer according to International 
classification based on morphology, special stains and IHC in small biopsies 
and compare the same with previous WHO classification. And finally to 
determine the diagnostic supremacy of one classification over the other and its 
therapeutic implications. 
 
  
MATERIALS AND METHODS: 151 cases Paraffin sections of small biopsy 
samples diagnosed as Non small cell lung carcioma will be subjected to routine 
H&E staining and supplemented to special stain for mucin (alcian blue/PAS)  
and IHC  markers p40(marker of SCC) and TTF1(marker of adenocarcinoma) 
 
RESULTS : Of the total 151 cases studied on morphological basis, 121 Cases 
were diagnosed as adenocarcinoma and squamous cell carcinoma. The 
remaining 30 cases diagnosed as NSCLC-NOS. In this study, According to 
IASLC/ATS/ERS, the percentage of NSCLC – NOS was minimised with the 
use of alcian blue/PAS  and the IHC markers p40 and TTF 1, from 19.86% to 
1.86%  
 
CONCLUSION : According to this study we conclude that multidisciplinary 
International Classification For  Lung Cancer is superior to 2004 WHO 
classification  in terms of  diagnostic, therapeutic and prognostic implications. 
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INTRODUCTION 
 
 Worldwide Lung carcinoma is the leading cause  of  cancer related 
mortality.  It occurs most often in the age group of  40 to 70 yrs.  It constitutes 
12.5%  of all newly detected cancers and 17.8%  of  cancer related deaths(1). 
 
 It has been classified mainly as two clinical subgroups as   
1. Non- small cell carcinoma of lung and 
2. Small cell  carcinoma of lung, with  the  incidence  of  80- 85%  and 15- 
20%  respectively(2). 
 
 Non- small cell carcinomas of lung are further sub typed as  
1. Adenocarcinoma  (40% of lung cancers), 
2. Squamous cell  or epidermoid carcinoma  (25-30%), 
3. Large cell or undifferentiated carcinoma  (10-15%), 
4. Adenosquamous  and 
5. Sarcomatoid type  ( less common types ) (2) 
 
 Around 68-72% of lung malignancies detected are not resectable  at 
diagnosis, as most of these patients  seek treatment with advanced disease. 
Now the primary method of diagnosing lung cancer are small biopsies and 
cytology. Until recently further classification of NSCLCs were not done, as it 
does not offer any survival advantage.  But with several specific therapeutic 
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options available today for patients with squamous, adenocarcinoma  or  
NSCLC-NOS, further sub-classification of  NSCLC based on small tissue 
biopsy and cytology using tumour markers and special stains have become 
necessary. (3,4) 
 
 WHO classification of lung cancer(2004) is based on resection 
specimens and primarily addressed only them. This classification  did  not  
propose any standardised criterias  for small biopsies and cytology in lung 
cancer(1). But the new multidisciplinary classification proposed by 
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG 
CANCER / AMERICAN THORACIC SOCIETY / EUROPEAN 
RESPIRATORY SOCIETY ( IASLC/ATS/ERS  2011)  provides, for the first 
time, certain  terms and criteria  for all major types of lung cancer based on 
cytology and small biopsy. 
 
 This study is aimed at classifying the lung cancer with small biopsies 
using special stains and immuno-histochemistry (IHC) markers  according to 
IASLC/ATS/ERS proposed new international  multidisciplinary classification, 
and to compare with previous  standardised  2004 WHO classification and its 
therapeutic implications. 
  
 
 
 
 
Aims and Objectives 
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AIMS AND OBJECTIVES 
 
 To classify lung cancer in accordance with the  new classification 
proposed by International association for the study of lung 
cancer/American thoracic society/European respiratory society 
(IASLC/ATS/ERS  2011) . 
 
 To compare with the previous  2004  WHO classification of lung 
tumours. 
 
 To determine the diagnostic supremacy of one classification over the 
other. 
 
 To assess the therapeutic implications of recent classification. 
 
  
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
Epidemiology: 
 Worldwide carcinoma of lung is the most common cancer  for several 
decades.  In 2012 ,it is estimated  to be 1.8 million new cases of lung 
carcinoma detected.this constitutes about 12.9% of all cancer cases. among 
these 58% of cases  occured in less developed countries. Lung cancer is the 
most common malignancy among  men worldwide (1.2million cases) with 
highest  age standardised rates in east and central Europe ( 53.5 per 1lakh 
population) and eastern Asia  (50.4 per 1lakh population).  Low incidence rates 
are observed in western and  middle Africa ( 1.7 & 2 respectively  per 1lakh 
population). 
 
 In women, the incidence of lung cancer  are generally low. the 
geographical pattern of lung cancer is little different and it mainly reflects the 
different historical exposure to tobacco smoke. Regarding incidence of this 
disease,  the highest  recorded are in  north America ( 33.8% )  and northern 
Europe ( 23.7%)  with relatively high rate in  Asia ( 19.2% ) and the lowest 
incidence in middle and western Africa.  Lung cancer remains the commonest  
cause of cancer  related mortality worldwide  and it is estimated  nearly  1 in 
every 5cases of deaths are due to lung cancer (about 1.59 million deaths 
accounting for 19.4% of all deaths). Because of  the high fatality and relative 
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risk of  survival variability  in different world regions, the geographical pattern 
in mortality from lung cancer closely follows those with incidence (5).  
 
 In India lung cancer remains the most common  and severe form of 
cancer among males. It accounts for 10.9%  of  cancer cases  and 13% of  
cancer related deaths ..Its incidence is low among Indian women.(5) 
 
Etiology and Pathogenesis: 
Tobocco smoke: 
 Among the risk factors, Smoking is the leading cause for lung cancer. 
At least 80% of lung malignancy related deaths are due to tobacco smoke. lung 
cancer occur mostly (86% ) in  active smokers and those quit smoking 
recently. There has been proven  statistical association between the incidence  
of lung malignancy  and smoking and it depends on 
 
1. The duration  
2. The quantity of cigarettes and 
3. Depth of inhalation of smoke 
 
 Smokers are at  increased risk(10 fold)  and heavy smokers ( > 40 
cigarettes per day) have  sixty times  more risk for lung cancer ,when 
compared to non smokers,.  susceptibility to tobacco carcinogens is more in 
women when compared to men . Despite  all this only 11% of heavy smokers 
develop lung cancer in their lifetime. This shows that additionally some 
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genetic factors also plays  a role. Studies shows  that industrial exposure to 
tobacco and second hand smoke  also contains many  human carcinogens.(6,7,8) 
 
 Clinical evidence is obtained from habitual smokers  through 
observation of all histological changes in their respiratory tract epithelium. 
Linear correlation is observed  between the intensity of  tobacco smoking  and 
the appearance of   changes in epithelial lining of lung. This change begins 
with squamous metaplasia,  CIS  and then invasive carcinoma, in that 
sequence(9). 
 
Radon: 
 It is a gas which occurs naturally and  is  obtained from breakdown of  
substances like uranium present in earth . Radon is identified as  second  
leading risk factor for lung cancer in united states.(8,10,11) 
 
Industrial hazards: 
 Exposure to occupational hazards accounts for  about 5-10% of  lung 
carcinoma  cases, in industrialised countries.  industrial  exposure such as 
ionising radiation, , asbestos, arsenic, cadmium, beryllium, vinyl chloride , 
silica ,nickel compounds, mustard gas ,chromium, coal products,  diesel 
exhaust etc  increases the risk of lung cancer . Exposure to ionising radiation is 
a moderate risk factor for this type of  malignancy as in patients treated with 
radiotheraphy and in atomic bomb survivors. 
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Asbestos:  
 Asbestos is an important risk factor for Lung cancer and the most 
common cancer in peoples exposed to asbestos is lung cancer.  Smoking in 
Asbestos workers  have  50 to 90 times increased risk  than do non-
smokers.(12,13) 
 
Air pollution: 
 Air pollution increases the risk for lung cancer. It may be due to both 
Outdoor or Indoor cause. Worldwide it constitutes about 5% of all lung cancer 
cases. Indoor air pollution may be responsible for increased risk among non 
smoking women in Asia including some parts of china. This risk is highest 
among women living in poorly ventilated homes where wood, coal and other 
solid fuels are burnt regularly. Fumes from unrefined vegetable oils also 
increases the risk.(11,12,14) 
 
Radiation therapy: 
 Radiation therapy to the chest as treatment for other malignancies ( eg: 
as for Hodgkins  disease or Carcinoma breast etc ) are at higher risk for lung 
cancer.(14) 
 
Geographical location: 
 People living in certain areas of south-America and south-Asia  with 
high  arsenic levels in drinking water are at increased risk.(14) 
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Family history: 
 Inheritance of certain DNA changes on a specific  chromosomes are at 
increased risk for carcinoma of lung. 
 
Dietary supplements: 
 Studies showed that smokers taking beta-carotene supplements develops 
lung cancer with increasing frequency. The possible role of other vitamins in 
decreasing the risk of lung malignancy, is not promising so for.(14) 
 
Molecular genetics: 
 Exposure to risk factors will cause genetic alterations in lining epithelial 
cells of lung, which accumulate and lead to malignancy. Some  molecular 
lesions are common for both clinical types ( small cell and non small cell lung 
cancer ), but some are very specific. 
 
Genes  frequently associated with lung cancer are , 
 Dominant oncogenes  such as  c-MYC, EGFR, c-MET, KRAS and c-
KIT(15) are inactivated  and / or deleted. 
 Tumour suppressor genes  such as p53, p16( INK4a) ,  RB1 and many 
loci on chromosome 3p. 
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So far the identified genetic factors involved in lung cancer are , 
1. In small cell carcinoma, C-KIT ( ~40-70%), 3p (100%) , p53(~90%), 
BCL2(70-90%), RB(~90%)  MYCN  and MYCL (20-30%) are  
commonly involved. 
 
2. In non-small cell lung carcinoma KRAS(10-15%), p53(50%), 
p16INK4a(70%), EGFR(25%) , ALK(5%) are involved .(15-18) 
 
ANATOMY AND HISTOLOGY OF LUNGS 
GENERAL CONSIDERATIONS: 
 
 The lungs are paired intra thoracic organs that in turn are divided into 
lobes. On right side it is divided into three as upper, middle and lower lobes. 
On left side into two as upper and lower lobes. There  is a rudimentary 
appendage arising from  upper lobe of left lung called lingula  which is the 
analog of the middle lobe on the right side. The lobes are divided by fissures 
and each have their own pleura investments. The lobes were further subdivided 
into broncho pulmonary segments. In an normal individual there were 
approximately 20 generations extending from trachea upto respiratory 
bronchioles. Airways are defined as follows 
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 Trachea  : Major  Cartilagenous airway, 
 Bronchi  : Cartilagenous airway and are usually greater than 1mm . 
 Bronchioles : These airways lack cartilage and are usually less than 
1mm.  
 Non-respiratory bronchioles : Represent all bronchioles proximal to 
respiratory bronchiole. 
 Terminal bronchiole:  The last non respiratory bronchiole is termed as 
terminal bronchiole. 
 Respiratory bronchioles: Airways where gaseous exchange takes place 
and are lined with alveoli in their walls. 
 
HISTOLOGY: 
 The respiratory tract is lined by pseudo stratified columnar epithelium 
composed primarily of ciliated columnar cells  interspread with mucous cells,  
and less number of brush cells, neuro-endrocrine cells, and migrated 
inflammatory cells. The height of the pseudo stratified epithelium decreases 
progressively towards the periphery of  lung. The   importance of this 
segmental anatomy for pathologist, radiologist, bronchoscopy specialist is in 
clearly defining the lesion location.(18) 
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ORIGIN: 
 The site of origin for lung cancer refers to the type of tissue from which 
the cancer cells develops (18,19.) Usually lung cancer is categorized by its site of 
origin into hilar and peripheral types, as these structures from where the 
disease originates are different . The majority of  the early lung cancers arising 
in  hilar regions are squamous cell carcinoma, whereas those early stage  
cancers arising in the peripheral areas of lung are adenocarcinomas.(19). 
Adenocarcinomas usually originates in glandular tissue whereas squamous cell 
carcinoma originates in the tissue that lines the organs and tubes of the lungs 
called epithelial tissues (20).  NSCLCs  such as  adenocarcinomas and large cell 
lung carcinoma are located typically in the peripheral areas of  lungs and can 
present as  either solitary nodule or masses (19). Squamous cell carcinoma and 
small cell carcinoma   are normally found to arise in the central portions of the 
lung and may be misdiagnosed as  collapsed lung (Atelectasis) or 
pneumonia(19). Small cell carcinoma are usually located in the main bronchi. 
this  type of malignancy appears to originates from the Kulchitsky cells, which 
in turn is a  component of the bronchial epithelium.(19). 
 
Precancerous lesions of lung: 
 According to the recently publicised  tumour classification system of 
WHO there are  three well defined precancerous lesions  of lung as 
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 Squamous dysplasia / carcinoma in-situ:  
 This represents the precursors of  SCC of lung. 
 
 Atypical Adenomatous hyperplasia (AAH) :  
 This adenomatous hyperplasia represents the precursor lesion for 
adenocarcinoma . it usually seen in peripheral lesions  and 
 
 Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: 
 This may progresses  to carcinoids. Other possible pre-neoplastic lesions 
are Squamous metaplasia (which progresses to squamous dysplasia,carcinoma 
in situ ), Adenomatous hyperplasia (precursor to AAH),   Basal cell 
hyperplasia, pulmonary fibrosis,  angiogenic  squamous  dysplasia  , etc.(21) 
 
 No precancerous lesion is identified for small cell carcinoma so far. But 
sometimes precursors of NSCLSs such as squamous dysplasia  or carcinoma 
in-situ be seen in the nearby airway mucosa.(21-27) 
 
Carcinoma of lung: 
 Like any other malignancy, Lung cancers arise by accumulation of 
genetic changes which alter and modify the normal bronchial epithelium to 
malignancy. Usually  these tumours found to arise in and around the hilum of 
lung. About 75% of these tumours  arises from first to third order bronchi. 
Most of the peripherally arising  lung cancers are adenocarcinomas. 
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LUNG CANCER TYPES 
Small cell carcinoma: 
 Of all lung cancers, Small cell carcinoma constitutes about 10-20% of 
them. Mostly  found to arise in male patients and in that more  than 85% are in 
smokers. Small cell  carcinoma of lung  is an highly aggressive  malignant 
tumour. Most commonly it appears as lesion in the central portion of lung , but 
it may also seen in peripheral regions. Macroscopilly it appears as greyish 
white to tan, soft, friable and extensively necrotic. Microscopically it appears 
as solid pattern, but there are other growth patterns like ribbon and streams, or 
ductules and  tubules, rosettes and pseudo rosettes may  also be seen .(28,29)  
according to betticher et al (30) 
 
 The  neoplastic cells are small round, oval or spindled with scant  
eosinophilic cytoplasm, finely granular chromatin ( salt and pepper 
chromatin), almost absent or inconspicuous nucleoli and nuclear moulding. (30) 
 
Combined small cell carcinoma : 
 A tumour with characteristics  of small cell variety with additional small 
components of either squamous cell carcinoma or adenocarcinoma. This type 
usually appears as hilar or periphral mass lesions or often presents with 
mediastinal  lymphadenopathy and or lobar lung  collapse. 
 
14 
 
 Among all lung cancers, Small cell variety is the most aggressive 
malignant tumour. It would have metastasized widely at diagnosis and it is 
almost incurable surgically. 
 
Non small cell lung carcinomas 
Squamous cell carcinoma: 
 Most cases of squamous cell carcinoma occurs in men. Among smokers 
it is the most common malignant lung tumour. This tumours are usually large 
at presentation arising in the central portions of lung, either from segmental or 
sub-segmental bronchi.(31,32)  But now the incidence of this tumours in 
peripheral of lung is also increasing.  Usually it may occurs as hilar or perihilar 
mass lesion. In central type lesions lobar or entire lung collapse may occur. It 
has a special tendency to undergo cavitation, central necrosis,etc . 
 
 According to suprun et al(33), histologically, these tumours shows 
keratinization (individual cells or pearl formation) with or without intercellular 
bridges. The degree of differentiation of tumours influence the presence of 
these features, being more prominent in well differentiated ones  and seen 
focally in poorly differentiated varieties. 
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Variants of scc: 
Papillary variant: 
 This variant of squamous cell carcinoma shows exophytic and endo-
bronchial growth invasion  in most of the cases. But sometimes limited intra-
epitheial spread without invasion is seen.(34) 
 
Clear cell variant: 
 This variant of scc contains most malignant cells featuring classical  
clear cytoplasm.(35) 
 
Small cell variant:  
 These are  poorly differentiated SCC with small tumour cells which  
retains the  morphological characteristics of NSCLCs  but with focal squamous 
differentiation.(36,37) 
 
Basaloid variant: 
 This  squamous cell carcinoma variant  shows peripheral  palisading of 
nuclei which is the prominent finding and it usually presents with very 
aggressive clinical course. Squamous cell carcinoma have better survival rate   
than adenocarcinoma.(29) 
 
Adeno carcinoma of lung: 
 Adenocarcinoma is the most common type of lung tumour  seen among 
women and non smoking men. This type usually tends to be smaller and 
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peripherally located at presentation. But rarely  it may also presents in central 
location as hilar or peri hilar mass lesions.  Cavitation is seen rarely. 
 
 Adjacent structures like pleura and chest wall are involved in 15% of 
cases. Presentation with hilar lymphadenopathy is less common with 
adenocarcinoma than with other types . Grossly the size varies widely and  
may  appear as solitary  or multiple mass lesions. 
 
Based on location ,Six macroscopic patterns are recognised. 
1. Peripheral tumour ( most commom type), 
2. Central or endobronchial tumour. 
3. Diffuse or lobar pneumonia like tumour. In this variety the underlying 
architecture is preserved which is a typical feature of  mucinous BAC. 
4. Bilateral diffuse lung disease. 
5. Diffuse interstitial fibrosis or localised scar.(38) 
6. Tumour invades  widely along the visceral pleura.(39). 
 
 Histologically it may appears as well differentiated tumours with well 
developed glandular pattern  to poorly differentiated solid mass. 
 
Histological subtypes of adenocarcinoma: 
1. Mixed Type :    
 Most common type of adenocarcinoma representing 80% of resected 
specimens. 
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2. Acinar Pattern:   
 It contains tubules and acini composed of columnar or cuboidal cells 
which may secrete  mucin.(29) 
 
3. Papillary Pattern : 
 In this type  secondary  and tertiary papillary structures are seen which 
replaces the underlying lung architecture. Tissue invasion and necrosis may be 
present. The lining cells may be mucinous and non-mucinous secreting 
cuboidal to columnar cells. Micropapillary  pattern of  adenocarcinoma, are 
usually  prognostically unfavourable varieties.(40) 
 
4. Bronchoalveolar pattern : 
 In this pattern malignant cells will grow along the alveolar structures 
(this is known as lepidic growth). but without  vascular, stromal,  or pleural 
invasion.(29) 
 
5. Solid Pattern:   
 This variety composed  usually of polygonal cell sheets which lacks 
tubules acini  and papillae but  mucin is seen in atleast five tumour cells. 
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Variants  of Adenocarcinoma of  lung: 
Mucinous (or colloid) adenocarcinoma. 
Fetal adenocarcinoma. 
Clear cell adeno carcinoma. 
 Signet ring adeno carcinoma. 
 
Large cell carcinoma: 
 These are undifferentiated carcinoma that lacks the architectural and 
cytologic features of squamous cell or small cell or glandular pattern.  9% of  
lung cancer patients are due to large cell carcinoma.(41-43) It usually presents as 
large peripheral mass. Histologically  it consists of sheets  of large polygonal 
cells  with characteristic vesicular nuclei,  nucleoli and moderate  cytoplasm. 
 
Variants : 
1. Large cell neuroendocrine carcinoma : 
 This type constitutes 3% of lung cancers.(42). The malignant cells are 
arranged in various patterns such as organoid, nesting, trabecular rossetes  or 
peritubular  palisading  paterns. (29,44). The cells are usually large with  
abundant cytoplasm and nucleus shows  prominent nucleoli. 
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2. Combined large cell neuro endocrine carcinoma : 
 This tumor shows combination of features  of  squamous cell carcinoma,  
adenocarcinoma, giant cell carcinoma  and  may be spindle cell carcinoma too. 
 
3. Basaloid carcinoma: 
 Here, the tumor cells are arranged in many patterns as  nodular, solid,  
trabecular,  and invasive growth pattern . May be  Peripheral palisading of 
cells are noted. The cells are monomorphic, small cuboidal to fusiform with  
nuclei showing  moderate hyperchromatism. (45) 
 
4. Lymphoepithelioma like carcinoma: 
 They show growth pattern, with tumor cells having large vesicular 
nuclei, and prominent nucleoli. This type of carcinoma show heavy lymphatic 
infiltration .(42-44,46) 
 
5. Clear cell carcinoma:  
 Large polygonal  tumour cells with clear, foamy cytoplasm.(47,48) 
 
6. Large cell with rhabdoid phenotype: 
 Rhabdoid cells containing tumour in which this rhobdoid cells should 
constitute atleast 10% of tumour cells. 
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Adeno squamous carcinoma: 
 It occupies about 0.4 to 4 % of all lung malignancies. Common at 
periphery of the lung. Microscopy shows features of both squamous cell 
carcinoma and adeno carcinoma, in which, each type should contribute atleast 
10% of the tumour.(49-51) 
 
Sarcomatoid carcinoma: 
 It occupies about 0.3 to 1.3% of all lung malignancies. Microscopically 
this shows components of sarcoma or sarcoma like differentiation. Five 
subtypes in this are  pleomophic type, spindle cell type, giant cell type,  
carcinosarcoma and pulmonary blastoma type.(52-56) 
 
Carcinoid tumours: 
 Typical and atypical carcinoids are the major types of carcinoid tumor.  
 
Other types of lung malignant neoplasms: 
 Other rare types include adenoid cystic carcinoma, mucoepidermoid 
carcinoma,  lymphomas,  sarcomas, and  epithelial- myoepithethelial 
carcinoma. 
 
CLINICAL FEATURES: 
 Symptoms include cough , chest pain, hoarseness , haemoptysis, 
,shortness of breath , fatigue, weight loss, new onset of wheeze (common in  
squamous cell carcinoma) 
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 Adenocarcinomas  are usually asymptomatic, and more often a 
incidental radiologic finding. 
 
 Small cell carcinoma is present with symptoms pertaining to distant 
metastasis.  
 
 The local effects of lung tumor can be  obstructive pneumonia, pleural 
effusion, chest pain/back pain which is  due to mediastinal invasion by the 
tumor itself.  
 
 Nerve entrapment by the tumor, to say, recurrent laryngeal nerve 
causing hoarseness, sympathetic nervous system leads to horner syndrome, 
phrenic nerve  leads to diaphragmatic paralysis. 
 
 Superior vena cava syndrome due to SVC obstruction by tumor 
 Pericardial involvement produce pericarditis and cardiac tamponade 
 Dysphagia due to  invasion  into oesophagus.  
 
 Metastasis leads to: 
 The symptoms related to the organs involved. Involvement of  liver, 
pancreas and adrenals produce symptoms like loss of weight, abdominal pain. 
Bone metastasis produce  bone pain. 
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 CNS involvement causes neurological symptoms such as dizziness, head 
ache, and vomiting.  
 
 Paraneoplastic syndromes common with lung carcinoma are 
hypocalcemia, hypercalcemia, carcinoid syndrome , cushing syndrome,  
gynacomastia etc. 
 
Other systemic manifestations : 
 Lambert-Eaton myasthenic syndrome due to autoantibodies directed 
against neuronal calcium channels(57). It is charecterised by peripheral 
neuropathy, acanthosis nigricans, hypertrophic pulmonary osteoarthropathy, 
hematologic abnormalities like anemia, thrombocytopenia, eosinophilia, 
leukemoid reaction, leukoerythroblastosis, etc., 
 
Course of the Disease: 
 Lung carcinomas are usually preceded  by  dysplasia lasting for years  
followed by carcinoma in situ for several years and presents as a mass lesion 
which becomes symptomatic. The lesion appears as a gray white ,firm to hard, 
which may show haemorrhage and necrosis at some foci.(20,21) 
 
 The neoplasm can grow intraluminally and present as a mass within the 
lumen. The tumour can also penetrate the wall of the bronchus and involve 
adjacent peribronchial tissues, carina, mediastinum etc. 
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 Local extension to pleura, pericardium, and the adjacent lymph nodes 
such as tracheal, bronchial, mediastinal lymph nodes may occur.  
 
 Distant metastasis occurs via  both lympatic and haematogenous routes. 
All tumours except squamous cell carcinoma will metastasize early . Distant 
metastasis to adrenals is more common (>50%), followed by  liver (30-50%), 
bone(20%),  and brain(20%).(46) 
 
Imaging in Lung Cancers: 
Pre and post diagnostic imaging done for various reasons 
1. For finding  a suspicious area that might be malignant. 
2. For staging of  the disease. 
3. Inorder to assess the effectiveness of treatment  
4. For the surveillance for recurrence of tumor 
 
 T.V Colby et al(59) found that the  various imaging modalities that have 
their role in diagnosing  lung cancer are  
 
X-ray: 
 The primary investigation to detect and characterise the lung mass.  It 
helps in assessing the involvement main bronchi / trachea. Also ,  helps in 
identifying lymphadenopathy , mediastinal invasion, and  pleural effusion. 
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Computed Tomogram:  
 This helps to locate the tumor. helps in assesing the size and shape of 
tumours. Also the adjacent areas of involvement and any  metastastic lesions 
in adrenals, liver , brain and other internal organs can be found. 
 
Magnetic Resonance Imaging: 
 Metastatic lesions of  brain and spinal cord etc., can be detected 
 
Ultrasonogram:  
 It detects pleural effusion. also guides for thoracocentesis, and 
diagnostic biopsy of peripheral lung  and lesions of mediastinum. 
 
Positron Emission Tomography( PET scan):  
 A form of nuclear imaging which detects biochemical changes in body 
tissues. Often, it is used as a whole body scan to detect early metastatic lesions 
and  tumour recurrence. 
 
 Literature stated that staging of cancer patients has been improved with 
the use of  PET (60-62) 
 
Bone Scan:  
 To detect any metastatic lesions in bones 
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INVESTIGATIONS TO DIAGNOSE LUNG CANCER: 
 The gold standard investigation for the diagnose of lung cancer is tissue 
diagnosis under microscopy. Many diagnostic techniques are available to 
obtain tissues are  
 
1. Sputum cytology 
2. Thoracentesis 
3. Excisional biopsy of  accessible nodes 
4. Flexible bronchoscopy (FOB) with or without transbronchial needle 
aspiration 
5. Transthoracic needle aspiration 
6. Video-assisted thoracoscopy, and 
7. Thoracotomy (63). 
 
 In view of selecting the appropriate test procedure, the diagnosing 
physician, should determine  which type of lung cancer is suspected. 
 
 Thoracotomy can be done in patients suspected to have early stage 
disease, which appears amenable to  surgery. (63-67). Staging and tissue 
diagnosis can be done with this (68). 
 
 To diagnose with sputum cytology, at least 3 samples of sputum must be 
collected; since this is a non-invasive test, even if it is negative, further testing 
can be done.(60,65,68) Presence of hemoptysis warrants sputum cytology. Also, 
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centrally located tumors needs sputum cytology. Specificity of sputum 
cytology in diagnosing lung cancer is 99% and its sensitivity for centrally 
located lung tumors is 71%, and for peripheral tumors is <50%. (60,66,69) It also 
aids in diagnosing  squamous cell carcinoma. 
 
 Thoracocentesis can be performed in case of pleural effusion. 
Malignacies of lung can be diagnosed with pleural fluid sampling. The 
sensitivity of thoracocentesis in diagnosing lung cancer is 80% and its  
specificity is < 90%. 
 
 In order to get a tissue sample, biopsy of an accessible lymph node  may 
also be taken. 
 
 If  the stage of the cancer types  are not clear, sputum cytology, flexible 
bronchoscopy (FOB), and transthoracic needle aspiration are the 
recommended test procedures.  
 
 Flexible bronchoscopy is done by passing scope along the bronchial 
lumen and taking tissue samples by bronchial washings and/or by biopsies. 
The sensitivity of  flexible bronchoscopy  in detecting the lung cancer is 88%. 
 
 According to De Wever W et al(60)  Placing catheters into patients lung 
should never be attempted without  the guidance of Computerized tomography 
(CT). The sensitivity as well as specificity of this test depends on the location 
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of tumor and site of tissue sampling. The sensitivity in diagnosing the centrally 
located tumors with the help of flexible bronchoscopy is 88%. The specificity 
for same is 90%. The sensitivity for peripherally located tumors falls to 60 to 
70% with this technique. 
 
 According to Rivera MP et al, With the guidance of CT or fluoroscopy, 
transthoracic aspiration with the use of appropriate needle is the procedure of 
choice  recommended for peripherally located  tumours with sensitivity of 
90%  and  specificity of 97%.  If the transbronchial needle aspiration done in a 
patient with peripheral tumour is not conclusive, and if the patient is not 
suitable for surgery, this technique is recommended. A major complication of 
this procedure is pneumothorax, which is seen in 25 to 30% of the patients 
undergoing  this  procedure . 
 
 Small peripherally located tumours with size < 2 cms in diameter, 
pleural effusion,  pleural tumours can be proceeded with Video assisted 
thoracoscopy.  Endoscopes are helpful in visualising the space between lungs 
and parietal pleura. It also  helps in detecting the small lesions in inter pleural 
space, to take tissue biopsy and to resect some lung cancers in early stage. It 
can prevent the attempt of thoracotomy, which is the major advantage of this 
procedure.  
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 Lastly in all cases where the tumour is resectable,  thoracotomy is 
routinely recommended for diagnosis and as treatment for early stage 
disease(60,70). 
 
SCREENING: 
 Since we know many types of lung cancer histologically,  finding a 
single biomarker is in fact a great challenge. Several such  biomarkers are 
being evaluated. The effective screening programs could help for early 
detection of lung cancers  which may increase the survival. One of the research 
projects at the Moffitt Cancer Research Center, has such an objective (71,72). 
Present research emphasises microscopic examination of sputum sample 
staining patterns. One of the possible screening tool is monoclonal antibodies 
(Mabs). The pattern and the intensity of stain of the Mabs and varying cell 
characteristics are now being analysed. The genetic and protein markers helps 
in  more understanding of tumor biology(72). The process of epithelial 
carcinogenesis can be due to mutation of some  particular genes, which can 
alter its control over abnormal cell growth. Heterogeneous nuclear 
ribonucleoprotein (hnRNP) is found to be useful marker for early detection of 
the disease in sputum cytology. Datas suggest that hnRNP is being expressed 
in most of the lung cancers before any morphologic abnormalities detected. 
 
 Other important biological markers found in lung cancers include: 
Tumor suppressor genes such as p53, Rb, p16, p21, the proto-oncogenes such 
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as c-myc, c-erB-1, K-ras ,  HER-2, HGF  and growth factors such as TGF-b, 
GRP/BN, PTHrP, IGF-I & II , FDGF, apoptotic factors and factors favouring 
angiogenesis such as Bcl-2, VEGF, respectively and gene amplification factor, 
HER-2 (71) These molecular markers are important in diagnosing pulmonary 
malignancies.It also helps to determine the prognosis as well as treatment 
regimen. According to the study presented by Duarte,et. al, 2005, many 
biological markers are found to be associated with greater frequency with 
various tumors(73) . Rb is found to be associated with 30% of NSCLC, whereas 
Rb  gene is found to be associated with positive  in 100% of SCLC. 
 
 The present clinical trial conducted by National Cancer Institute on a 
large scale called as Prostate Lung Colorectal and Ovarian Screening Trial 
(PLCO)(74,75). Its main objective is to ascertain the efficacy of screening tools 
used in trial and to evaluate the mortality rate associated with the specific type 
of malignancy under study (142). The main disadvantage of this trial is that the 
conventional chest x-ray fails to detect the lung malignancies in early 
stages(74).   Another such study is the the National Lung Screening Trial 
(NLST).  This trial compares spiral CT scans with the conventional chest x-
rays and determines which screening tool is more effective in  reducing the 
mortality due to lung cancers. Spiral CT detects the lung nodules which are be 
detected by conventional chest x-rays; This has created moral and ethical issue 
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since spiral CT has been proved to detect the lung cancers at early stages as 
compared to chest x-rays (76).  
 
CLASSIFICATION OF LUNG CANCER 
WHO Classification (ANNEXURE II) 
IASLC/ATS/ERS  Classification in small biopsy and cytology 
(ANNEXURE III) 
 
Prognostic factors: 
 Early detection of cancer favours increased survival; but unfortunately, 
none of the screening  programmes are proved to be successful(79). Due to lack 
of early detection of  this malignancy, it has  become one of the most lethal 
among all cancers; Mortality rate in  lung cancer have superceded the same 
due to colorectal, prostate and breast cancer combined. Patients are 
asymptomatic till the advanced stage, which is the major drawback. American 
Cancer Society observed that  only 15% of these cancers  are diagnosed in 
early stages , i.e. Stage I. In patients with lung cancers, the five year survival 
rate is 15%, which is due to the  lack of programmes for early diagnosis . 
 
 National cancer institute showed that, in lung cancer, the 5 yr survival 
rate is only 15% for whites  and the same for blacks is 11%.(80,81) 
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Age :  
 Lung cancers in patients < 40years will have poor prognosis. The 
aggressiveness of the  cancer and presentation at advanced stages are the 
probable cause for this..(80) 
 
Sex :    
 Women have worse prognosis than men. This is partially due to the fact 
that, women have high incidence of  lesions in advanced stage  and  
adenocarcinoma is the commenest type in women.(81,82) 
 
Location :  
 Superior sulcus tumors have better prognosis rather than tumors at other 
site. Peripherally located squamous cell carcinomas  have better prognosis than  
those located centrally.(83-85) 
 
Stage of the disease : 
Tumour size :   
 Large tumours have worser prognosis than small tumours of same 
histological type.  In adenocarcinoms showing both  in-situ and invasive 
components, the site of the invasive component is an independent predictor of 
the survival rate.(86-88) 
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Cell type and degree of differentiation: 
 Squamous cell carcinoma is found to be the most type of lung cancer 
among other lung cancer types.(89-92)  For well differentiated tumours,  5 
year survival rate is 40%  for those undergoing resection,  for 
moderately differentiated tumours, it is 20%  and  for poorly 
differentiated tumours 5 year survival rate is 7%   . 
 Among adenocarcinomas, papillary carcinoma showing micropapillary 
pattern have the worst prognosis than other types. Prognosis of bronchio 
alveolar carcinoma seems better than ordinary adenocarcinoma.(93-94) 
 The presence of tumour giant cells in large cell carcinoma have worse 
prognosis.(95) 
 Small cell carcinomas have worse prognosis. The 5 year survival rate 
for small cell carcinoma patients  is only  <  2%(95) 
 If the  lymphoplasmacytic component is found prominently in tumor 
under microscopy, then it  favours  good prognosis.(94) 
 Stronger expression of TTF -1 in patients with NSCLC,  indicates better 
survival.(96,97) 
 
Other poor prognostic factors are : 
 Local and regional extension of the tumor, to say, chest wall invasion, 
vascular  invasion, regional lymph node involvement  .(98) 
 The presence of  tumor cells in plueral fluid (99). 
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 Peripherally located adenocarcinomas and also undifferentiated large 
cell carcinomas  which are found to be in association  with  fibrotic 
scar.(100,101) 
 The presence of rhabdoid cells.(78) 
 RAS and  P21 expression in NSCLC, and NMYC gene expression in 
small cell carcinomas(102-105) 
 p53 and HER 2/neu  over expression  (102-105) 
 
TREATMENT FOR LUNG CANCER 
Four basic modes of treatment available for lung cancer  
1. Sugery 
2. Radiation therapy 
3. Chemotherapy 
4. Targeted therapy 
 
 Treatment plan varies with many factors such as the type of cancer, 
stage at presentation, side effects of particular treatment, patients preference, 
health of the patient. 
 If NSCLC is confined to the lung, it is considered as early stage of the 
disease and surgical resection can be done.(106) Post operative radiotherapy with 
or without chemotherapy can be considered.(107). If patient cannot withstand 
surgery, radiotherapy is the choice of treatment. 
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 Various types of surgeries performed are lobectomy, wedge resection,  
segmentectomy and  pneumonectomy. 
 
 Early stage samll cell lung carcinoma should be treated with 
chemotherapy and concurrent radiotherapy. 
 
 Once the tumor started spreading beyond hemithorax with metastasis to 
mediastinal lymph nodes, surgery is no longer recommended and the treatment 
of choice includes radiotherapy and chemotherapy. 
 
 External beam radiotherapy and radioisotope therapy are the two types 
of radiotherapies given in lung cancers.  
 
 Chemotherapy includes platinum based Cisplatin and Carboplatin(107) 
and non platinum based drugs such as Docetaxel, Paclitaxel, Gemcitabine, 
Irinote can.  
 
 Distant metastasis is treated with chemotherapy alone.(107) 
 
MOLECULAR TESTING AND TARGETED THERAPY 
 Molecular testing reveals various specific charecters of the tumor which 
influences the diagnosis, prognosis and treatment with targeted therapy. 
 
 Targeted therapy have promising benefits if given to appropriate 
patients. Here, the therapy is targeted against cancer specific genes / proteins. 
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 Anti angiogenesis therapy blocks the formation of new blood vessles. 
Bevacizumab, a monoclonal antibody  targeted against VEGF is a potential 
inhibitor of angiogenesis. 
 
 EGFR mutations are seen in 10% - 15% of NSCLC, and common in 
adenocarcinomas. Geftinib and Erlotinib are the tyrosine kinase inhibitors 
targeted against intracellular  tyrosine kinase domain of  EGFR. Hence, 
tyrosine kinase inhibitors are the first line treatment for NSCLC.(108) 
 
 Rearrangement of ALK gene is seen in 5% of NSCLC and is most 
common in nonsmokers with adenocarcinoma. Drugs that are targeted against 
ALK mutation includes, Crizotinib and Certinib.(109-111) 
 
 Several new markers are evolved which may be associated with the 
outcome on targeted therapy.  They are ROS1, BRAF , FGFR, HER2, 
PIK3CA, KRAS. 
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Treatment for NSCLCs  in advanced stage: 
 
 
RECOMMENDATIONS BY IASLC/ATS/ERS NEW 
MULTIDISCIPLINARY INTERNATIONAL CLASSIFICATION, FOR 
SMALL BIOPSY AND CYTOLOGY SPECIMENS WERE: 
 For cytology as well as small biopsy specimens, if  a clear 
differentiation can be done,  which satisfies the standard morphologic 
criteria, further specific typing of NSCLC into squamous cell 
carcinomas and adenocarcinomas can be done with morphology alone. 
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 The term  NSCLC - NOS  must be  used as infrequently as possible and  
it should only be used if the  diagnosis cannot be made out by 
morphology and /or by  special staining / IHC. 
 When  small biopsy / cytology specimen is used  in addition  with 
special stains for diagnosis, it should be clearly noted whether the 
diagnosis is achieved with only  light microscopy or in combination 
with special stains. 
 The term non-squamous cell carcinoma which is used by clinicians, 
should not be used by pathologists while reporting. Pathologists should 
report  NSCLC  only as ADC , SQCC and  NSCLC - NOS. 
 The tissue specimens  received by pathologists just be used judiciously 
and preserved to the maximum, as more tissues will be needed for 
further molecular studies.(113-115)    
 In small biopsies / cytology specimens,  if any invasive pattern is found 
in adenocarcinoma ,it is to be reported as a lepidic  growth pattern . The 
term minimally invasive ADC and ADC- in situ  should not be used. 
 The term large cell carcinoma,  should be used  only in  resected 
specimens as  thorough  sampling of  tumour is not possible in small 
biopsy/cytology specimens. 
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 If the tumor shows sarcomatoid features characterised by malignant 
giant cells or spindle cells with nucleus showing  pleomorphism  should 
be classified according to guidelines above as  NSCLC favouring ADC 
or NSCLC favouring  SCC based on features of  glandular pattern or 
squamous features  respectively. when these features are absent   it is to 
be reported as NSCLC - NOS with a word about sarcomatoid features.. 
 Only if  the tumor shows neuro endocrine morphology, neuro endocrine  
IHC  markers are performed then. 
 Further classification of  NSCLC- NOS is possible with the use of IHC, 
into NSCLC favouring ADC  and NSCLC favouring SCC. 
 It is advised to use minimal stains for further subclassification of   
NSCLC-NOS.  
 It is recommended to use only one marker  for adenocarcinoma or one 
marker for squamous cell carcinoma.  
  Currently, the single best marker for diagnosing  adenocarcinoma is  
TTF-1. Staining with diastase - periodic acid schiff,  alcian blue/ PAS 
stains  or mucicarmine  also play a role in diagnosing adenocarcinoma. 
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 The specific marker for diagnosing  SCC is Polyclonal  p40  rather  than 
the monoclonal p63 . p40 is likely to surpasses p63 as a best IHC  
marker in diagnosing   squamous cell carcinoma. 
 In  NSCLC -NOS , the cases which shows  TTF-1 positive and /or 
mucin positive, but  p40 and p63 negative are termed as NSCLC 
favouring adenocarcinoma. similarly those cases with p40 and/or p63 
positive but TTF-1 and mucin stain negative are termed as NSCLC 
favouring SCC with comment on whether special stains are used  to 
arrive at diagnosis. 
 In case, one population of tumour cells show TTF-1 reactivity and 
another population  of tumor cells show postive for squamous cell 
markers, possibility of adenosquamous carcinoma should be 
considered. 
 But if  TTF-1 as well as p40 are negative  and fails to show any 
squamous or glandular morphology, the diagnosis still remains as 
NSCLC-NOS. 
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ALTERATIONS SUGGESTED BY IASLC/ERS/ATS INTERNATIONAL 
CLASSIFICATION OF LUNG MALIGNANCY IN RESECTED SPECIMENS: 
 
1.  The term bronchoalveolar carcinoma  is discarded. 
 In the new multidisciplinary classification,  BAC is discarded. Originally, 
broncho alveolar carcinoma  is defined as a non-invasive lesion, but since 
then, it is used to denote broad  group  of tumours which includes 
 
 Nonmucinous BAC. This is defined as solitary non invasive  small  
peripheral adenocarcinoma. This type will have 100% 5 year survival 
rate.(116) 
 Minimally invasive  small peripheral adenocarcinoma with 5 year 
survival upto 100%.(117,118) 
 Invasive adenocarcinoma with mixed subtype.(119,120) 
 Nonmucinous  and mucinous  adenocarcinoma, which is known as BAC  
earlier.(120) 
 Advanced mucinous adenocarcinoma( stage 4) with low survival rate.(4,6) 
 
 In the new multidisciplinary  classification, ‘BAC’ is referred to as "former 
BAC" 
 
 2.  New concepts were introduced for 
 
41 
 
 Small  solitary peripheral  adenocarcinoma  with  size less than or equal to 
3cm,with pure lepidic growth  without invasion with 100% disease specific 
survival as adenocarcinoma in situ(AIS).(116) 
 
 Small, solitary peripheral adenocarcinoma with size less than or equal to 
3cm, with predominantly lepidic growth with invasion, with 100% disease 
specific interval  as minimally invasive adenocarcinoma(  MIA).(117,118) 
 
3. Former invasive adenocarcinoma with mixed subtype is replaced by 
predominant pattern..   
 According  to 2004 WHO classification more than 90% of lung 
adenocarcinoma are of mixed subtypes. In this new  international 
classification this mixed subtype is replaced with  predominant pattern. It is 
recommended to choose one  predominant pattern  based on  recording of  
patterns in 5% increments.(121,122) 
 
4. In multiple lung adenocarcinoma patients it is recommended comprehensive 
histological subtyping of  heterogenous, complex lung adenocarcinoma to 
determine if the tumours  are synchronous, metachronous or metastasis.(123) 
 
5. It recommends  the term lepidic predominant adenocarcinoma in place of  
previously classified  as mixed subtype ,predominantly non mucinous 
BAC.(117) 
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6. New histological type of  Micropapillary predominant adenocarcinoma is 
introduced . This is associated with poor prognosis.(122) 
 
7. In new international classification,  invasive mucinous adenocarcinoma, 
fetal, enteric and colloid adenocarcinomas are introduced as new 
variants.(124) 
 
 Acccording to Edwards et al (127), only  10-15% of  lung cancer  
patients undergo resection and the preoperative diagnosis confirmed. So 
treament for  most of the  patients  is based on diagnosis with small 
biopsy/cytology  specimens alone. 
 
According to Suprun et al, (33 )  
 The criteria for diagnosis of  SCC are  
The presence of Keratin formation  and/or Intercellular bridges. In cases 
if  the tumor lacks such features, the intraepithelial in- situ like 
extensions along the bronchus are present in SCC.  Both  adeno and 
small cell carcinoma  do not replace the bronchial epithelium to a 
considerable extent.  And most of these cases are either well 
differentiated or moderately differentiated. This feature aids in  
histological typing of lung cancers in small biopsy specimens.(125) 
 
The grading of squamous cell carcinoma cannot be done in small biopsy 
specimens.(126) 
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 The diagnosis of adenocarcinoma seems to be more challengeable as the 
presence of mucin and gland formation are frequently not present in 
small biopsies, which calls for mucin stains to demonstrate the presence 
of glandular elements. 
 
 According to the study of  Edwards et al,(127)  the diagnosis of large cell 
carcinoma is possible only with  resected specimens and not on  small 
biopsies. This is because,  they are the  poorly differentiated forms of 
adenocarcinoma, squamous cell carcinoma, or neuroendocrine 
carcinoma  and also most major types of lung carncers contain foci of 
features of  large cell carcinoma . 
 
 Recent data showed that the high percentage (30-50%) of  NSCLC-NOS  
has been diagnosed in small biopsies. (128-130) and   data from the registry 
of epidemiology surveillence shows   the increasing frequency of this 
diagnosis.(131) 
 
 
ALCIAN BLUE/PAS ( Mucin stain) : 
              Mucins are a glycoprotein with high molecular weight, that was 
synthesized and secreted by epithelial mucosal cells, mainly the goblet 
cells (132). Mucins are classified into acidic mucins and neutral mucins 
histochemically. This will include sialomucins and sulphamucins.  
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            Many adenocarcinomas like cancers of colon, breast, ovary, 
lung, etc will  increase  mucin  production(133).  
 
            Acid mucins and neutral mucins will be differentiated using 
Alcian blue- PAS staining.(134). This property will be of value in 
demonstrating  even minimal acid mucin.  Mucin stains  is a valuable 
markers but its use in lung carcinoma in terms of sensitivity and 
specificity may be variable. This is a defining characteristics of lung 
adenocarcinoma, although not positive in all cases.(134) 
 
THYROID TRANSCRIPTION FACTOR-1: 
 TTF-1 is a DNA  binding protein  expressed  normally in thyroid,  
lungs, and also in specific locations of diencephalon(135). Its role in lung tissues 
is,  it regulates the gene expression of  surfactant and clara cell secretory 
protein. the study of such transcription factors in human lung tumours are 
helpful in understanding the molecular events of the noeplastic transformation 
of  such lung tumors (136).Several reports  says that in lung cancers the 
expression  of  TTF-1  varies with different histological subtypes(137-140). 
 
 According to J.Korean et al(143),  TTF-1 was expressed in 62.5 - 90% of  
ADC  and in 89-100% of small cell carcinomas, but it was not found or very 
less frequently found in SCC ( 0-25%) and  large cell carcinomas ( 0-24%). 
Many reports highlights the usefulness of TTF1 in differentiating lung cancer 
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from non pulmonary tumours.TTF-1 appears to be more  sensitive and specific 
marker for diagnosing adenocarcinomas and small cell carcinoma of lung. It is 
a useful prognostic marker and used in conjucation with  proliferative marker  
ki 67.(143) 
 
p40(p63 delta): 
 p40 (p63 delta), a new marker,  is the shortest variant of  human p53. It 
is a valuable marker in cases where p63 has been traditionally used. p40 has 
equal  sensitivity as p63 in detecting squamous cell carcinoma. 
 
 But p40 exhibits superior specificity when compared with p63. 
Moreover, p40 helps in the early detection of breast cancers , prostate cancers 
and lung cancers. 
 In lung cancer,  the p40 is a very specific marker for squamous basal 
cells. It helps to differentiate squamous cell carcinoma from ADC. In breast 
cancers,  the p40 stains the myoepithelial cells along the ducts of  mammary 
glands, and helps in detecting ADH and DCIS. 
 
 In prostate cancer,  p40 staining of basal cells inside the ducts of the 
prostatic glands will  indicates PIN.  
 
 p40 and p63 have equal sensitivity in pulmonary squamous cell 
carcinomas, but former is more specific. In rare instants, p40 is positive for 
adenocarcinomas.but it will be weak,  focal, and seen in isolated malignant  
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cells, easily distinguisable from  squamous cell carcinoma which is diffusely 
reactive. 
 
 p40, a nuclear marker has excellent sensitivity and  specificity, makes 
itself a more specific marker for SCC. Diffuse labelling of p40 indicates SCC, 
whereas its absence warrants a strong discussion against this diagnosis.(144-148) 
 
  
 
 
 
 
Materials and Methods 
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MATERIALS AND METHODS 
 
 This study is a retrospective and prospective study of lung cancer in 
small biopsies conducted in the Institute of pathology,Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai during the period 
between July 2013 to June 2014. 
 
 A total of 13042  cases were submitted to our department the Institute of 
pathology, Madras medical college during the period of July 2013 to June 
2014 for histopathological examination. Out of them, 392 were lung cases. 
Among them 19 cases were pneumonectomy specimens, 50 were lobectomy 
specimens and 323 were small biopsies (Transbronchial, Endobronchial, Open, 
Ultrasound  guided biopsies and Computed tomography guided core biopsies). 
 
Inclusion criteria: 
 FOB biopsies and CT Guided biopsies from clinically and radiologically 
suspected cases of lung cancer. 
 
Exclusion criteria: 
1) Cases treated with prior Chemotherapy and radiotherapy. 
2) Small cell carcinoma. 
3) Resected  specimens. 
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METHOD OF DATA COLLECTION: 
 Detailed history of the cases regarding age, sex, site, tumor location, 
radiological findings, FOB findings, cytological findings were obtained for all 
the 323 cases. Out of these 
 
Inadequate for opinion         -     23 
Non neoplastic                     -     95 
Suspicious of malignancy   -      12 
Malignancy                          -      189 
 
Among the malignant cases, 
NSCLCs         - 153 cases 
Small cell lung carcinoma    - 13 
Others                                - 23 
 
 These 153 Non small cell lung carcinoma cases were reviewed and sub 
classified  based on H&E morphology according to WHO classification 
criteria. Tumours were sub typed as adenocarcinoma  if  it  showed features of  
gland formation and/ or mucin production, squamous cell carcinoma if it 
showed   features of  keratinazation or intercellular bridges ,  large cell 
carcinoma  ( undifferentiated non small cell carcinoma)  if  it lacked  both  
glandular  or  squamous patterns.  In these 153 cases, 2 cases were excluded 
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because they were resected specimens. Out of these 151  cases, based on 
morphology seen in biopsy further segregation done as follows:  
 
 Group 1: Cases that could be  subtyped  by morphology alone as 
adenocarcinoma or squamous cell carcinoma (121 cases), 
 
 Group 2: Cases that are  poorly differentiated non small cell lung 
carcinoma (NSCLC-NOS) (30 cases). 
 
 All  30 cases of poorly differentiated non small cell lung carcinomas 
(NSCLC-NOS) from group 2 and 10 cases each of   poorly differentiated 
adenocarcinoma and squamous cell carcinoma selected randomly from group 1 
were included  for special staining and IHC study for further classify the 
NSCLC-NOS group into favouring  adeno or squamous subtypes and to study 
the efficency of special stains( ALCIAN BLUE/PAS) and markers ( TTF-1, 
p40). 
 
 Five –micron thick paraffin sections were cut and stained with 
combined  mucin stain, TTF-1 and p40 and the tumours were sub-typed based 
on the algorithm followed by the IASLC/ATS/ERS 2011 
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 Alcian Blue / PAS staining was done as per protocol given in 
ANNEXURE-V. 
 
IMMUNOHISTOCHEMICAL EVALUATION: 
Antigen Vendor Species Dilution Positive control
TTF- 1 BIOGENIX Mouse Ready to use lung Adenocarcinoma
P40 BIOGENIX Mouse Ready to use Lung squamous cell carcinoma 
 
Immunohistochemistry was done as per protocol given in ANNEXURE-
VI. 
 
INTERPRETATION AND SCORING SYSTEM: 
 The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization(nuclear), percentage of cells stained 
and intensity of reaction. 
 
 In this study, for evaluation of TTF1 and p40 proteins,  greater  than 
10% expression of the tumour marker within tumour cells is considered as 
positive. Cases  with no focal areas of positive staining and with less than 10% 
staining are considered negative. 
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STATISTICAL ANALYSIS: 
 Immunohistochemical analysis was done in paraffin embedded tisse 
samples using the statistical package for social science software version 
15.5 which consisted computing the frequency counts and percentages 
for qualitative variables and mean for quantitative variables. 
 P value of 0.005 was taken as cut-off point to determine statistically 
significant results. 
  
 
 
 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 
 In the study period of 12 months from July 2013 to June 2014,a total  of  
13042 specimens were received in the Institute of  Pathology, Madras Medical 
College for histopathological examination. 
 
 Total numbers of lung specimens received were 392 cases, of these 19 
cases were pneumonectomy specimens,50 cases were lobectomy 
specimens,323 were small biopsy specimens. (TABLE:1 CHART:1)  
 
TABLE 1 : TYPES   OF  LUNG SPECIMEN: 
Pneumonectomy 19(4.84%) 
Lobectomy 50(12.75%) 
Small biopsy 323(82.39%) 
Total 392 
 
 
4.84%
12.75%
82.39%
CHART:1 TYPES OF  LUNG SPECIMEN
Pneumonectomy
Lobectomy
Small biopsy
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 Among the 323 small biopsy specimens ,number of bronchial biopsy 
were 137,CT guided biopsy were 153,USG guided biopsy were10,open biopsy 
was 1 and transbronchial biopsy were 22. (TABLE:2,CHART:2) 
 
TABLE :2 TYPES OF  SMALL BIOPSY 
CT guided biopsy 153(47.36%) 
Bronchial biopsy 137(42.41%) 
USG guided biopsy 10(3.09%) 
Transbronchial biopsy 22(6.81%) 
Open biopsy 1(0.30%) 
Total 323 
 
 
 
 
47.36%
42.41%
3.09%
6.81%
0.30%
CHART:2 TYPES OF SMALL BIOPSY
CT guided biopsy
Bronchial biopsy
USG guided biopsy
Transbronchial biopsy
Open biopsy
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 Totally 189 malignant cases have been reported with  the percentage of  
56.6%, among which 183 malignancies  were found to be in small biopsy 
cases. Among  the 183 small biopsy cases 152 were non small cell  carcinoma 
of lung, 13 were small cell lung carcinoma, 2 were malignant mesothelioma , 
11 were metastatic deposits in lung, 1 was solitary fibrous tumour, 1 was 
carcinoid tumor. Out of 6 resected specimen, 1 was giant cell tumor, 1 was 
large cell  lung carcinoma, 1 was spindle cell carcinoma, 1 was SCC,  2 were 
typical carcinoid tumors. 
 
 The most common lung malignancy were NSCLCs  (Adenocarcinoma, 
SCC, adenosquamous cell carcinoma, spindle cell carcinoma, large cell 
carcinoma) which constitutes 153 cases (80.95%),small cell lung carcinoma 
constituted 13 cases which accounts for 6.8%. 
 
 Metastatic carcinoma constitutes 11cases which accounting 5.8%,the 
other histological subtypes accounts for 2% .(carcinoids-1%,giant cell tumor-
0.5%) (TABLE :3 CHART:3) 
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TABLE 3:HISTOLOGICAL SUBTYPES OF LUNG CARCINOMA 
HISTOLOGICAL 
SUBTYPES NUMBER OF CASES PERCENTAGE 
NSCLC 153 80.95% 
Smallcell lung 
carcinoma 13 6.8% 
Metastatic deposits 11 5.8% 
Carcinoids 3 1.59% 
Giant cell tumor 1 0.5% 
 
 
 
                                              
 
80.95%
6.8%
5.8%
1.59%
0.5%
CHART:3 HISTOLOGICAL SUBTYPES OF LUNG 
CARCINOMA
Non small cell lung carcinoma
Small cell lung carcinoma
Metastatic deposits
Carcinoids
Giant cell tumor
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 Of the total 189 lung tumours, Squamous cell carcinomas were most 
common accounting for 79 cases which accounts for 
41.9%,adenocarcarcinoma constituted  46 cases accounting for 24%,30 cases 
were poorly differentiated non small cell lung carcinoma(16%) ,small cell lung 
carcinoma were 13 cases constituted 6%,11 were metastatic 
deposits(4%),carcinoids were 3 cases(1%), giant cell carcinoma, spindle cell 
carcinoma, solitary fibrous tumor  and large cell carcinoma each constitutes 1 
case and accounting for o.5%. (TABLE: 4& CHART:4  ) 
 
TABLE:4   HISTOLOGICAL  SUBTYPE OF LUNG TUMOURS: 
Histological subtypes Number of cases Percentage 
Squamous cell carcinoma 79 41.9% 
Adenocarcinoma 46 24% 
NSCLC-NOS 31 16% 
Small cell lung carcinoma 13 6% 
Carcinoids 3 1% 
Spindle cell carcinoma 1 0.5% 
Large cell carcinoma 1 0.5% 
Large cell NEC 1 0.5% 
Solitary fibrous tumor 1 0.5% 
Giant cell tumor 1 0.5% 
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 In small biopsy specimen the non small cell carcinoma  of lung 
(NSCLCs) was classified according   to WHO classification  into squamous  
cell carcinoma, adenocarcinoma, poorly differentiated non small cell lung 
carcinoma (which lack squamous or adeno differentiation). Among this SCC 
of lung  were the most common type which accounts for 78 cases (51.65%),   
adenocarcinoma  constituted  44 cases (29.1%), poorly differentiated NSCLC 
were 30 cases(19.8%), large cell carcinoma was 1 case (0.65%) and large cell 
neuroendocrine carcinoma  was 1 case (0.65%) .large cell neuroendocrine 
carcinoma was already confirmed by neuro endocrine marker such as NSE and 
41.9%
24%
16%
6%
1% 0.5%
0.5%0.5%
0.5%
0.5%
CHART:4 HISTOLOGICAL SUBTYPES OF LUNG 
CANCER
Squamous cell carcinoma
Adenocarcinoma
poorly differentiated NSCLC
Small cell lung carcinoma
Carcinoids
Spindle cell carcinoma
Large cell carcinoma
Large cell NEC
Solitary fibrous tumor
Giant cell tumor
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chromogranin .  For Large cell carcinoma there was no material in the block. 
so these 2 cases were not included in the  further study.(TABLE:5 CHART:5) 
 
TABLE 5:NON SMALL CELL LUNG CARCINOMA SUBTYPES 
ACCORDING TO WHO CLASSIFICATION 
Histological types of 
NSCLC Numbers of cases Percentage 
Squamous cell carcinoma 78 51.65% 
Adenocarcinoma 44 29.1% 
Poorly differentiated 
NSCLC 30 19.8% 
 
 
 
                                     
  
51.65%
29.1%
19.8%
CHART:5
Histological subtypes of NSCLC
Squamous cell carcinoma Adenocarcinoma Poorly differentiated NSCLC
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 According to WHO classification the adenocarcinomas were subtyped 
into acinar, papillary, bronchoalveolar, solid, mixed type and grading  
bronchoalveolar as well differentiated, acinar and papillary as moderately 
differentiated and solid as poorly differentiated. Among these the mixed type 
were 17 cases(38.6%), solid type were 11 cases(25%), acinar type were 8 
cases(18.8%), papillary type  and bronchoalveolar type were 4 each accounts 
for 9%. (TABLE :6,CHART: 6) 
 
TABLE 6: ADENOCARCINOMA SUBTYPES ACCORDING TO WHO 
CLASSIFICATION  BY MORPHOLOGICAL FEATURES 
 
Adenocarcinoma subtypes Number of cases Percentage 
Bronchoalveolar 4 9% 
Papillary 4 9% 
Acinar 8 18.8% 
Solid 11 25% 
Mixed 17 38.6% 
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 Peak incidence for all types of  non small cell lung carcinoma is 51-
60yrs. In this study, the youngest age at presentation is 30yrs. The mean age is 
57.62 yrs. 15 cases were observed in the age of above 70 years. 84.76% of the 
cases were seen  in the age group of  40 to 70 years. (TABLE:7 & CHART:7) 
  
9%
9%
19%
25%
38%
TABLE:6 ADENOCARCINOMA SUBTYPES 
ACCORDING TO WHO CLASSIFICATION
Bronchoalveolar
Papillary
Acinar
Solid
Mixed
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TABLE 7: AGE WISE DISTRIBUTION OF NSCLCs 
AGE GROUP Number of cases Percentage 
30 years 1 0.66% 
31-40 years 7 4.6% 
41-50 years 30 19.8% 
51-60 years 55 36.4% 
61-70 years 43 28.4% 
70-80 years 14 9.27% 
>80 years 1 0.6% 
Total 151  
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 Squamous cell carcinoma and adenocarcinoma had a peak incidence in 
the age group of  51-60 years with mean age for SCC being 57.96 years and 
for adenocarcinoma  57.02 years. TABLE:8,CHART:8 
 
TABLE :8 AGE WISE DISTRIBUTION OF SQUAMOUS CELL 
CARCINOMA AND ADENOCARCINOMA 
 
AGE 
GROUPS SCC ADENOCARCINOMA 
NSCLC -
NOS 
30 Years 1(1.2%) 0 0 
31-40 years 4(5.1%) 2(4.5%) 0 
41-50 years 13(16.6%) 10(22.2%) 8(25.36%) 
51-60 years 23(29.48%) 15(34%) 12(38.7%) 
61-70 years 20(25.64%) 9(20.45%) 9(29.3%) 
71 -80 years 6(7.69%) 6(13.6%) 2(6.4%) 
> 80 years 1(1.2%) 0 0 
TOTAL 78 44  
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 Among the 78 squamous cell carcinoma, 65 cases (84.4%) were 
reported in males and 12 cases (15.5%) were reported in females. The male to 
female ratio was 5.6:1. In adenocarcinoma, males constituted 26 cases (59%) 
and females constituted 18 cases (40.9%) and the  male to female ratio was 
1.44:1. 
 
 From this study it was observed that  both  squamous cell carcinoma and 
adenocarcinoma ,are more common in males than females. But when 
compared to squamous cell carcinoma ,the females are more frequently 
affected by adenocarcinoma  with near equal incidence in males. 
(TABLE:9,CHART:9) 
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TABLE:9 SEX WISE DISTRIBUTION OF N 
ON SMALL CELL LUNG CARCINOMA 
 
SEX SCC ADENOCARCINOMA NSCLC-NOS 
MALE 66(84.4%) 26(59%) 25(80.6%) 
FEMALE 12(15.5%) 18(40.9%) 6(19.35%) 
TOTAL 78 44 31 
 
p value-0.005,chi square-10.6 
 
 
 
 Cough , breathlessness and weight loss were the most common clinical 
presentation for both squamous cell carcinoma and adenocarcinoma. 
TABLE:10,CHART:10 
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TABLE:10 CLINICAL FEATURES OF SQUAMOUS  
CELL CARCINOMA 
 
Clinical features Number of cases Percentage 
Cough 71 91% 
Hemoptysis 51 65.38% 
Breathlessness 21 26.92% 
Chest pain 34 43.58% 
Weight loss 64 82% 
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TABLE:11 CLINICAL PRESENTATION OF ADENOCARCINOMA 
Clinical features Number of cases Percentage 
Cough 42 95.5% 
Hemoptysis 4 9% 
Breathlessness 27 61.3% 
Chest pain 21 47.72% 
Weight loss 32 72.7% 
 
 
                                          
 In this study ,squamous cell carcinoma most commonly  occured in 
smokers than nonsmokers and adenocarcinoma were more common in non 
smokers than smokers.p value-0.001 chisquare test-13.6 TABLE:12, 
CHART:12. 
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TABLE:12 SMOKING ASSOCIATION IN SQUAMOUS CELL 
CARCINOMA AND ADENOCARCINOMA 
 
 H/O SMOKING
NO H/O 
SMOKING 
QUIT 
SMOKING TOTAL
SCC 55(70.5%) 19(24.35%) 4(5.12%) 78 
ADENOCARCINOMA 16(36.36%) 24(54.54%) 4(9.09%) 44 
TOTAL 71 43 8  
p value-0.001 chisquare test-13.6 
 
 
 Regarding the site of prevalence of tumours out of 151 cases 84 cases 
were seen in the right side of the lung (55.62%) and 67 cases in the left side of 
the lung (44.67%).The lobar distribution was as follows:  55 cases in the right 
upper lobe (36.42%), 9 cases in the right middle lobe ( 5.96% ),  20 cases in 
the right lower lobe (13.24%), 35cases in the left upper lobe (23.17%), 14 
cases in the lingual (9.27%) and 18 cases in the left lower lobe (11.27%). 
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 Among the 151 cases of non small cell lung carcinomas, most common 
location of tumour is in right upper lobe (36.42%) followed by left upper lobe 
(23.17%). Least common  site of location is in right middle lobe(5.96%).  In 
this study right lung was more commonly affected than left lung . TABLE:13, 
CHART:13 
 
TABLE:13 SITE DISTRIBUTION OF NON SMALL CELL LUNG 
CARCINOMA 
 Upper lobe Middle lobe Lower lobe Total 
Rt lung 55(36.42%) 9(5.96%) 20(13.24%) 84(55.62%) 
Lt lung 35(23.17%) 18(11.92%) 14(9.27%) 67(44.37%) 
 
 
 Among the 78 patients with  squamous cell carcinoma , 27 cases 
(34.61%) were seen in right upper lobe,  left upper lobe constitutes 21 
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(26.92%).  Majority of squamous cell carcinoma were seen in right lung 
constituting 55.12%. Table:14 & CHART:14 
 
TABLE:14 SITE DISTRIBUTION OF SQUAMOUS CELL 
CARCINOMA: 
 Upper lobe Middle lobe Lower lobe Total 
Right lung 27(34.61%) 4(3.84%) 12(15.38%) 43(55.12%)
Left lung 21(26.92%) 5(5.12%) 9(11.53%) 35(44.87%)
 
 
 
 Out of 44 cases of adenocarcinoma ,11 cases were seen in the right 
upper lobe of the lung with the percentage of 25%,followed by left upper lobe  
which constitutes 8 cases(18.18%).TABLE:15&CHART:15  
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TABLE:15 SITE DISTRIBUTION OF ADENOCARCINOMA 
 Upper lobe Middle lobe Lower lobe 
Right lung 11(25%) 5(11.36%) 6(13.63%) 
Left lung 8(18.18%) 7(15.90%) 7(15.90%) 
                                  
 
 
 
 With available radiological features in this study , nodular and mass 
lesions are proved to be  malignant .  Some diagnosed as non-neoplastic lesion 
radiologically such as cavitatory lesion,  consolidation changes,  
emphysematous changes etc  also  turned out to be malignant pathologically.              
 
 Most common radiographic finding of squamous cell carcinomas was 
found to be mass lesion and  seen  commonly as   hilar mass. Other less 
common findings are consolidation,  bullae, emphysematous lesion and cavity 
formation. TABLE:16 ,CHART:16 
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TABLE:16 VARIOUS RADIOLOGICAL FINDINGS IN SQUAMOUS 
CELL CARCINOMA OF LUNG CANCER 
 
RADIOLOGICAL FINDINGS NUMBER OF CASES 
Mass 49(55.05%) 
Hilar mass 9(10.11%) 
Cavity and consolidation 7(7.86%) 
Multiple nodules 1(1.12%) 
Bullae and emphysematous changes 1(1.12%) 
Rib erosion 3(3.37%) 
Opacity 2(2.24%) 
Chest wall invasion 4(4.49%) 
Mass with consolidation 2(2.24%) 
Mediastinal invasion 2(2.24%) 
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 Most common radiological finding of adenocarcinomas was found to be 
mass lesion and opacity. Other less common findings are consolidation, hilar  
prominance and pleural effusion. TABLE:17, CHART:17 
 
TABLE:17    VARIOUS RADIOLOGICAL FINDINGS IN 
ADENOCARCINOMA OF LUNG 
 
RADIOLOGICAL FEATURES NUMBER OF CASES 
Mass 36(52.17%) 
Cavity &consolidation 5(7.24%) 
Fibrosis 2(2.89%) 
Multiple nodules 4(5.79%) 
Hilar prominence 2(2.89%) 
Chest wall invasion 3(4.34%) 
Mediastinal lymphadenopathy 6(8.69%) 
Pleural effusion 6(8.69%) 
Rib erosion 3(4.34%) 
Bilateral lung involvement 2(2.89%) 
Opacity 11(15.94%) 
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 With available radiological findings, local metastasis such as 
mediastinal, chest wall and rib invasion were seen in  26 cases(13.9%), 
regional metastasis (mediastinal node, cervical node, supraclavicular  and 
scalene node metastasis)  were seen in 9 cases (9.27%) and distant metastasis 
such as  contralateral lung  involvement, multiple nodules  in brain ,liver and 
adrenal  metastasis  seen  in 6 cases (9.93%) TABLE:18&CHART:18 
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TABLE:18 STAGE OF NON SMALL CELL LUNG  
CARCINOMA AT PRESENTATION 
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CARCINOMA 
LOCAL
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METASTASIS NSCLC PERCENTAGE 
LOCAL 26 17.21% 
REGIONAL 19 12.58% 
DISTANT 21 13.90% 
UNSTAGED 66  
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 Among the 78 cases  of squamous cell carcinoma, local metastasis  were 
seen in 11 cases (14.10 %), 9 cases (11.53%) showed regional metastasis and 8 
cases (10.25%) showed distant metastasis . 
 
 Among the 44 cases of adenocarcinoma, 9 cases(20.45%) showed Local 
metastasis, Regional metastasis and Distant metastasis  accounts for  5 
(11.36%)  and 10 (22.72%) cases respectively. 
 
 In 31 cases of poorly differentiated NSCLCs,  the local,  regional and  
distant  metastasis  each  accounts  for   2 cases (6.45%),    1 case (2.27%) and 
3 cases (6.81%) respectively. Of   these  two,  the metastasis  is  more  
common  in  adeno carcinoma.   
 
 Among the 26 cases of  local metastasis chest wall invasion like rib and 
sternum involvement  were seen in 14 cases, mediastinal invasion  accounts 
for  12 cases. 
 
 Among the  21 cases with distant metastasis, separate lesion in  
ipsilateral or contralateral lung  were seen in 10 cases, 7 cases showed brain 
metastasis, 2 cases showed liver metastasis  and adrenal metastasis was seen in 
1 case. TABLE :19&CHART:19 
 
  
76 
 
 
TABLE : 19 STAGE OF THE TUMOUR AT PRESENTATION FOR 
HISTOLOGIC SUBTYPES OF NON SMALL CELL LUNG 
CARCINOMA 
 
STAGE SCC ADENOCARCINOMA NSCLC-NOS 
LOCAL 11(14.1%) 9(20.45%) 2(6.45%) 
REGIONAL 9(8.97%) 5(11.36%) 1(2.27%) 
DISTANT 8(10.25%) 10(22.72%) 3(6.81%) 
UNSTAGED 50(64.10%) 20(45.45%) 25(80.64%) 
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 With the available fibroptic bronchoscopic findings,  both SCC and  
adenocarcinoma may present  with or without mass and can also be  seen  with  
normal mucosa. All the polypoidal lesion identified in this study  showed  
squamous cell carcinoma.TABLE:20&21 ,CHART:20&21 
 
TABLE:20  FOB FINDINGS IN SCC OF LUNG 
FOB Findings Number of cases Percentage 
Normal mucosa 6 7.69% 
Inflamed mucosa 6 7.69% 
Narrowed bronchus 6 7.69% 
Polypoid mass 5 6.41% 
Mass 36 46.15% 
Total 59  
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 With the available FOB findings, most of the squamous cell carcinoma 
and adenocarcinomas are presented with endo bronchial growth. 
 
TABLE:21 FOB FINDINGS IN ADENOCARCINOMA 
FOB FINDINGS NUMBER OF CASES PERCENTAGE 
Inflamed mucosa 4 9.09% 
Normal 3 6.8% 
Narrowed bronchus 3 6.8% 
Mass 22 50% 
Total 32  
 
                   
 The cytological findings were available for 37 cases. Among the 
37cases, 28 were bronchial wash cytology, sputum were 7 and pleural fluid 
were 4. Bronchial wash positive for SCC and adenocarcinoma were 11 and 7 
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cases respectively. Most of sputum cytology were positive for squamous cell 
carcinomas. TABLE :22&CHART:22 
 
TABLE:22  CYTOLOGICAL FINDINGS 
 
Bronchial wash Pleural fluid Sputum 
POS NEG POS NEG POS NEG 
SCC 11 5 1 2 5 1 
ADENOCA 7 3 1 0 0 1 
 
 
 
 Among the 26 bronchial wash cytology cases,11 cases with squamous 
cell carcinoma and 7 cases with  adenocarcinoma were correlated with biopsy  
with the percentage of  60.23%.  TABLE:23 &CHART:23 
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TABLE:23 BRONCHIAL WASH CYTOLOGY AND BIOPSY 
CORRELATION 
 Correlated Non correlated 
SCC 11 5 
ADENO CA 7 3 
TOTAL 18(69.23%) 8(30.76%) 
 
 
 
 FNAC from Supraclavicular lymphnode were positve in 4  squamous 
cell carcinoma cases  and  in 1 case of adenocarcinoma. 
 
 Subtyping  of  NSCLC-NOS  was  done  based on the algorithm given 
by  IASLC/ATS/ERS International multidisciplinary team such as  the tumours 
which are positive for  TTF-1  and or mucin positive as NSCLC favouring 
adenocarcinoma  and those tumours which  are positive for  p40   are termed as 
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NSCLC favouring squamous cell carcinoma. if both TTF-1/ mucin stains and 
p40 are positive then the  possibility of adenosquamous carcinoma should be 
considered. But if both TTF-1/mucin and  p40 are negative  and fails to show 
any squamous or glandular morphology, the diagnosis still remains as 
NSCLC-NOS. TABLE: 24 
 
TABLE:24-SUBTYPING OF NSCLC BASED ON MUCIN STAIN AND 
IHC MARKERS 
Markers ADC SCC ADENOSQ NSCLC-NOS 
AB/PAS + - +/- - 
TTF-1 + - + - 
P40 - + + - 
 
 For mucin stains, in group1,  7 out of 10 adenocarcinomas were positive 
and in group 2, 12 out of 30 were positive. Mucin stains  was negative in 3 
cases of  proven adenocarcinoma from group 1.TABLE:25 & CHART: 25 
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TABLE:25 MUCIN STAIN IN NSCLC: 
 
 SCC ADENO NSCLC-NOS 
POSITIVE 0 7 12 
NEGATIVE 10 3 18 
TOTAL 10 10 30 
 
p value  -  0.005   chi square test   -  10.5 
 
 
 
 
 Regarding TTF-1, from group 1, 9 out of 10 cases of adenocarcinoma  
were positive and 16 out of 30 from group 2 were positive. TTF-1 was 
negative in all the poorly differentiated SCCs. TABLE:26 & CHART 26. 
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TABLE:26 TTF-1 EXPRESSION 
 SCC ADENO NSCLC-NOS 
POSTIVE 0 9 16 
NEGATIVE 10 1 14 
TOTAL 10 10 30 
 
p value  - 0.000    chi squre test - 16.5 
 
 
. 
 Regarding p40, in group 1, all 10 cases of squamous cell carcinoma 
were positive and in group 2 ,11 out of 30 cases were positive.  TABLE:27 & 
CHART:27 
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TABLE:27 p40 EXPRESSION IN  NSCLCs 
 SCC ADC NSCLC-NOS 
POSITIVE 10 0 11 
NEGATIVE 0 10 19 
TOTAL 10 10 30 
 
p value - 0.000       chi square    - 21.4 
 
 
 
 
 TTF-1 was expressed in 50% of  the adenocarcinoma cases and p40 was 
positive in 42% of  squamous cell carcinoma. Both markers were positive in 1 
case and it was considered adenosquamous carcinoma. 6% of the tumours 
were negative for both markers and were considered as  NSCLC-NOS. 
TABLE:28 
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TABLE:28 SUBTYPING OF NSCLCs BASED ON  IHC MARKERS 
TTF-1 p40 Subtypes Percentage Number of cases(50) 
+ - ADC 50% 25 
- + SCC 42% 21 
+ + ADENOSQ 2% 1 
- - NSCLC-NOS 6% 3 
                                               
 According to IASLC/ATS/ERS, squamous cell carcinoma were the  
commonest subtype  accounting for 58.27% of cases. According to WHO 
classification, NSCLC-NOS accounts for 19.86%. But in this study with the 
use of Mucin stain, TTF-1 and p40 markers,   its  percentage minimised into 
3%  because of subcategorization.  TTF-1 and mucin stain positive cases 
were   subtyped as  favouring  adenocarcinoma and p40 positive cases were 
subtyped as favouring squamous cell carcinoma. 3% of cases were negative 
for both  TTF-1 and p40 ,so it was still subtyped as NSCLC-NOS category. 
TABLE:29 & CHART:29 
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TABLE:29 SUBTYPES NON SMALL CELL LUNG CARCINOMA 
BASED ON  IASLC/ATS/ERS CLASSIFICATION: 
 
Subtype Number of cases Percentage 
Adenocarcinoma 59 39.07%/ 
Squamous cell ca 88 58.27% 
NSCLC-NOS 3 1.98% 
Adenosquamous ca 1 0.66% 
Total 151  
 
 
CHART:29 SUBTYPES NON SMALL CELL LUNG CARCINOMA 
ACCORDING TO IASLC/ATS/ERS CLASSIFICATION 
 
 
 According to  the classification by IASLC/ATS/ERS, most predominant 
type of adenocarcinoma was solid  subtype which accounts for 18 cases and 
next common subtype was acinar which constitutes 12 cases. Other subtype 
39.07%
58.27%
1.98% 0.66%
Adenocarcinoma
Squamous cell ca
NSCLC-NOS
Adenosquamous ca
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like lepidic predominant type of adenocarcinoma accounts for 5 cases, 
micropapillary pattern constitutes 2 cases and papillary pattern was 6 cases. 
TABLE:30&CHART:30 
 
TABLE:30 ADC SUBTYPES BASED ONIASLC/ATS/ERS 
CLASSIFICATION 
Subtypes Number of cases Percentage 
Acinar 12 20.33% 
Papillary 6 10.16% 
Lepidic 5 8.4% 
Micropapillary 2 3.38% 
Solid 18 30.50% 
Favour adenocarcinoma 16 27.11% 
Total 59  
 
 
20%
10%
9%
3%
31%
27%
CHART: 30 ADENOCARCINOMA SUBTYPES  BASED ON 
IASLC/ATS/ERS CLASSIFICATION
Acinar
Papillary
Lepidic
Micropapillary
Solid
Favour adenocarcinoma
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  According to WHO classification,mixed subtype was constituted 
62.79%.It was further subtyped according to the presence of predominant 
pattern into cinar (46.15%), papillary(19.23%), lepidic(3.84%), micropapillary 
(7.69%), solid type.(23.07%) TABLE:31 
 
TABLE:31 SUBTYPING OF MIXED TYPE ACCORDING 
IASLC/ATS/ERS CLASSIFICATION 
2004 WHO classification IASLC/ATS/ERS 
 
 
MIXED SUBTYPE 26(62.79%) 
Acinar subtype 12(46.15%) 
Papillary subtype 5(19.23%) 
Lepidic subtype1(3.84%) 
Solid subtype 6(23.07%) 
Micropapillary subtype 2(7.69%) 
 
 According to this study,  on comparing   WHO classification and 
IASLC/ATS/ERS 2011 classification,   
 
 In the new classification , lepidic pattern adenocarcinoma was used 
instead of bronchoalveolar carcinoma -non mucinous subtype (3.31%) of 
WHO classification and 2 cases of micropapillary carcinoma were detected 
which is not included in the WHO classification.TABLE:32 
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TABLE:32 COMPARISION OF WHO CLASSIFICATION AND 
IASLC/ATS/ERS CLASSIFICATION IN SUBTYPING OF 
ADENOCARCINOMA 
 
2004 World health organization 
classification (n=43) 
2011 classification by Travis et al 
(n=43) 
Bronchoalveolar     -  3( 9.30%) 
Non mucinous 
Not applicable 
Lepidic predominant adenoca- 
3(9.30%) 
Bronchoalveolar -Mucinous -
2(4.54%) 
Mucinous adenoca-Lepidic -1(2.32%) 
Acinar  -1(2.32%) 
Acinar                     -1(2.32%) Acinar                       13(32.5%) 
Papillary                 - 3(6.97%) Papillary                     8(18.60%) 
Solid                        -8(18.60%) Solid                           14(32.5%) 
Mixed                      -27(62.79%) Not applicable 
Not applicable Micropapillary           2(4.65%) 
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 According to IASLC classififcation, with the use of AB/PAS stain,TTF-
1 and p40, 30 cases of non small cell lung carcinoma-not otherwise specified 
type were subtyped into favouring adenocarcinoma which constitutes 50%  
(n=15), favouring  squamous cell carcinoma which constitutes   36.66% 
(n=11) of cases, possible adenosquamous carcinoma were 3.33% (n=1) and 
unsubtyped were 10%(n=3).TABLE:33 
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CHART:32 COMPARISION WHO CLASSIFICATION AND 
IASLC/ATS/ERS CLASSIFICATION
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2011
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TABLE:33 SUBTYPING OF  NSCLC-NOT OTHERWISE SPECIFIED 
2004 WHO classification IASLC/ATS/ERS 
 
NSCLC-NOS(30 Cases) 
Favouring  adenocarcinoma-15(50%) 
Favouring  squamous cell carcinoma-
11(36.66%) 
Possible  Adenosquamous -1(3.33%) 
NSCLC-NOS-3(10%) 
       
 Based on this study,  on comparing   WHO classification and 
IASLC/ATS/ERS 2011 classification,   
 
 Squamous cell carcinoma was the commonest  type identified.  
 Based on  WHO classification , NSCLC- NOS category  constituted 
19.86%.  of total but according to new  international multidisciplinary 
classification with the use of mucin stains ,TTF-1 and p40  not 
otherwise specified category  was minimised to 1.86%. In new 
classification ,it was further subtyped into favoring adenocarcinoma, 
favoring squamous cell carcinoma ,possible adenosquamous cell 
carcinoma. 
 Among the total 151 cases of NSCLCs ,Regarding adenocarcinoma, 
instead  of mixed subtype ( 17.85%) of WHO classification   the 
presence of  predominant pattern  is  used in new classification as 
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lepidic (1.32%), acinar (7.84%), papillary (3.31%), micropapillary 
(1.32%), and solid (3.97%) subtypes . 
 In the new classification , lepidic pattern adenocarcinoma ( 1.98%) was 
used instead of bronchoalveolar carcinoma -non mucinous subtype 
(1.98%) of WHO classification. 
 2 cases of micropapillary carcinoma were detected which is not included 
in the WHO classification. 
 1 case of large cell carcinoma and sarcomatoid carcinoma each  
diagnosed according to WHO classification, were grouped into  NSCLC 
-NOS in new classification. TABLE:34 &CHART :34 
 
TABLE: 34   COMPARISION OF 2004 WHO CLASSIFICATION AND 
IASLC/ATS/ERS CLASSIFICATION 
WHO CLASSIFICATION IASLC/ATS/ERS 
Squamous cell carcinoma -51.65% Squamous cell carcinoma-51.65% 
Not included in 2004 WHO Favoring SCC-7.28% 
Adenocarcinoma  Adenocarcinoma 
Mixed subtype-17.88% 
     
Not included 
Acinar    -0.66% Acinar-8.60% 
Bronchoalveolar -non mucinous-
1.98% 
Lepidic predominant 
adenocarcinoma-3.31% 
Bronchoalveolar -mucinous-1.32% Mucinous adenocarcinoma-1.32% 
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WHO CLASSIFICATION IASLC/ATS/ERS 
Papillary  -1.98% Papillary-5.29% 
Solid          -5.29% Solid -9.27% 
Not included Micropapillary-1.32% 
Not included in 2004 WHO 
classification 
Favoring adenocarcinoma with use of 
IHC and special stain 9.93% 
NSCLC -NOS  19.86% NSCLC NOS-1.98% 
Adenosquamous carcinoma-0 Adenosquamous carcinoma-0 
Not included 
With IHC and special stain-possible 
adenosquamous-0.66% 
Large cell carcinoma-0.54% 
Non small cell carcinoma -NOS -
0.54% 
Sarcomatoid carcinoma-0.54% 
Poorly differentiated NSCLC with 
spindle &/or giant cell carcinoma-
0.54% 
                                         
CHART:34 COMPARISION OF 2004 WHO CLASSIFICATION AND 
IASLC/ATS/ERS CLASSIFICATION 
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Colour Plates 
  
SQUAMOUS CELL CARCINOMA
FIGURE:1 Well diffentiated squamous cell carcinoma
100X     HPE NO:60/14
FIGURE:2 Well diffentiated squamous cell carcinoma
400X      HPE NO:60/14
POORLY DIFFERENTIATED SQUAMOUS CELL CARCINOMA 
FIGURE:3  Poorly differentiated squamous  cell carcinoma 
100X    HPE NO:1594/14
FIGURE:4 Poorly differentiated squamous cell carcinoma 
400x HPE NO:1594/14
FIGURE:5 Adenocarcinoma –mixed type (Papillary and solid pattern)
100x     HPE NO:2618/14
FIGURE:6 Adenocarcinoma –mixed type (Papillary and solid pattern)
400x     HPE NO:2618/14
ADENOCARCINOMA WITH MIXED PATTERN
ADENOCARCINOMA –MIXED TYPE
FIGURE :7 Adenocarcinoma –mixed type (papillary and micropapillary)
100x    HPE NO:4308/13
FIGURE :8 Adenocarcinoma –mixed type papillary and micropapillary)
400x    HPE NO:4308/13
ADENOCARCINOMA –ACINAR PATTERN
FIGURE:9 Adenocarcinoma with acinar pattern 
100x    HPE NO:11378/13
FIGURE:10  Adenocarcinoma with acinar pattern 
400x    HPE NO:11378/13
FIGURE:11 Adenocarcinoma –lepidic pattern 
100X    HPE NO:10058/13
FIGURE:12 Adenocarcinoma –lepidic pattern 
400X    HPE NO:10058/13
ADENOCARCINOMA-LEPIDIC PATTERN
ADENOCARCINOMA –PAPILLARY  PATTERN
FIGURE :13 Adenocarcinoma –papillary type
100X    HPE NO:6679/13
FIGURE:14 Adenocarcinoma –papillary type
400x     HPE NO:6679/13
ADENOCARCINOMA –SOLID TYPE
FIGURE:15 Adenocarcinoma –solid type
100X     HPE NO:5527/14
FIGURE:16 Adenocarcinoma –solid type
400X     HPE NO:5527/14
ADENOCARCINOMA-MUCINOUS TYPE
FIGURE:17  Adenocarcinoma –Mucinous type
100X    HPE NO:7491/13
FIGURE:18  Adenocarcinoma –Mucinous type
100X    HPE NO:7491/13
ALCIAN BLUE/PAS -POSITIVE
FIGURE:19 Neutral  mucin positive adenocarcinoma
400X      HPE NO:11378/13 
FIGURE:20  Neutral  mucin positive adenocarcinoma
400X      HPE NO:701/14 
TTF-1 EXPRESSION
FIGURE:21 Strong nuclear positivity of TTF-1 in favoring adenocarcinoma
400 X   HPE NO:2400/14
                      
FIGURE:22 strong nuclear positivity in poorly differentiated adenocarcinoma
400X      HPE NO:6167/14
p40 EXPRESSION 
FIGURE:23 Strong nuclear positivity in
 poorly differentiated Squamous cell carcinoma
400X       HPE NO:644/14
FIGURE:24 strong nuclear positivity in favouring 
squamous cell carcinoma
400 X   HPE NO:5997/14
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DISCUSSION 
 Lung cancer is the leading  cause of cancer and cancer related mortality 
around the world and most of the  chemotherapeutic drugs  used  today lack 
adequate efficacy and specificity.  
 
 In India ,lung cancer has prepondarance to males constituting 10.9% all 
cases of cancer and 13% of all cancer related mortality. Mostly lung cancer 
affects people in 4th to 6th decade. Even with the recent advances available in 
treatment, the prognosis of the lung cancer still remains very poor. 
 
 85% of all lung cancers are non small cell lung carcinomas and 
adenocarcinoma is the commonest histologic type seen. Until recently, the 
histological subclassification of NSCLCs  had no clinically or therapeutic 
value(149).   But now with the availability of  targeted therapy and its differential 
activity and adverse effects based  on the type of the tumour,  precise sub 
typing of non small cell lung carcinoma has become mandatory as it has direct 
impact on treatment and prognosis. 
 
 The NSCLC has to be further subclassified into more accurate subtypes 
on small biopsy such as squamous cell carcinoma and  adenocarcinoma  , 
whereever possible as it serves  several purposes like  
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1. EGFR mutations should be tested in adenocarcinoma ,adenosquamous 
carcinoma and NSCLC-NOS .Because EGFR  TK inhibitors is the 
primary treatment available   for  adenocarcinoma of lung.(150) 
 
2. Those with adenocarcinoma histology or NSCLC-NOS showed better 
outcome with pemetrexed . Gemcitabine  has shown improved outcome 
in patients with SCC.151,152) 
 
3. When Bevacizumab is used  in  patients with SCC of lung,  life 
threatening haemorrhage can occur.(153) 
 
 Most  of lung cancers diagnosed presents in  advanced stage and 
resection rates were very low ,possible only in10 to 15 % of cases. So these 
few cases only will undergo complete  histological examination. currently as 
the 2004 WHO classification for lung cancer, is based on resected specimens, 
the application of this classification has limited value. But now with more 
therapeutic options other than resections available,  the diagnosis based on 
small biopsy and cytology became the primary method. 
 
 On comparison with The current WHO classification of lung cancer , 
the newer classification provided by IASLC/ATS/ERS 2011 has  included the 
criteria for diagnosing lung cancer  in small biopsy and cytology. 
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 This is a retrospective and prospective study conducted between july 
2013 to june 2014 in which 151 cases of  non small cell lung cancer diagnosed 
at our institute were selected. On classifying them according to 2004 WHO 
classification, 121 cases were morphologically subtyped and 30 cases  were 
classified as  NSCLC-NOS.These NOS specified cases were further sub 
classified using  Special stains (ALCIAN BLUE/PAS) and tumour markers  
(TTF-1 for adenocarcinoma and p40 for SCC). These special stains and 
markers are also used in selected cases of proven poorly differentiated  Adeno 
and squamous cell carcinoma ( 10 cases each of ADC and SCC of lung ) to test 
their efficiency in diagnosing   NSCLCs. Based on these  all the cases are 
classified according to the new IASLC/ATS/ERS international classification 
for the lung cancer. These results were  compared with 2004 WHO 
classification of lung cancer. 
 
 Madras medical college is a tertiary referral center and in the institute of 
pathology ,about 1.44%  were reported as lung cancer among the specimens 
received during the period of july 2013 to june 2014. Among the entire lung 
specimens received for histopathological examinations, 48.21% of the cases 
were reported to be malignant. Among the malignant cases, NSCLC accounts 
for 80.95% and SCLC accounts for 6.8%. This correlates  with study done by 
Navada S et al(154), according to which most common type of lung cancer is 
NSCLC and it accounts for 80-85%. 
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 This study showed that  SCC of lung  are the most common subtype 
which constitutes 51.65% followed by adenocarcinoma ( 29.1%) . This  
correlates  with study done by Delik Erman et al(155)   which says 60%  of 
cases were squamous cell carcinoma and 30% were adenocarcinoma. 
 
Squamous cell carcinoma: 
 In this study squamous cell carcinoma entity constitutes the predominant 
type of non small cell lung carcinoma .(155) 
 
 Squamous cell carcinoma was diagnosed histologically based on the  
presence of intercellular bridges and keratin formation. In the absence of these 
features ,it can be diagnosed on small biopsy  based on the features like 
intraepithelial   in- situ like extension along the bronchus. These features are 
not seen in other carcinomas  such as small cell  or adenocarcinoma. Suprun 
H et al(33). In our study ,all the cases of squamous cell carcinoma showed 
intercellular bridges and keratinisation. 
 
 Among the 151 cases, 78 cases (41.9%) come  under this category and 
showed  male predominance with 66 cases(84.4%) with male to female ratio 
was 5.6:1. The predominant age group of involvement was 51to 60 years, in 
which 23 cases(29.48% with the mean age of 57.96 years) were reported . One 
case was reported under the age of  30 years. 7 (8.89%) cases were reported 
above  70 years. 
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 This  finding correlates with study done by Delik Erman et al (155),            
according to which  NSCLCS  has  predilection  in the age group of 50-80 
years. Only 3% of cases presented before 30 years. 
 
 Cough ,breathlessness and weight loss were the most common clinical 
presentation of squamous cell carcinoma. According to Bach PB et al(156), 
common symptoms of lung carcinomas are persistent cough, hemoptysis, chest 
pain, shortness of breath , hoarseness and repeated respiratory infections, e.g. 
bronchitis, pneumonia.  
 
 Out of  the total 78 cases of squamous cell carcinoma, 55 cases(70.5%)  
were associated with history of smoking. This was correlated with study done 
by Satcher D et al(157),  who found that  most common cause of lung cancer in 
both men and women is was smoking and had strongest association with 
smoking was seen with SCC. 
 
 Most of the SCC were found in the right upper lobe constituting  
34.61%%(n=27)  followed by left upper lobe constituting   26.92% (n=21 ) of 
cases.  This showed that the prevalence  of squamous cell carcinoma were seen 
in the upper lobes. This correlates with the study done by Davies DF et al.(158) 
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 Most common radiographic finding of squamous cell carcinomas was 
found to be central or hilar mass lesion.This  correlates with the study done  by  
Minna, JD et al.(159)  
 
 According to Sharma SK et al(160),growth, necrotic material and 
inflamed mucosa were the most common findings in fibroptic bronchoscopy. 
Similarly in this study also with the available FOB findings, most of the 
squamous cell carcinoma was presented with endobronchial  growth and other 
findings are inflamed mucosa and narrowed bronchus.All the polypoidal lesion 
showed squamous cell carcinoma histology. 
 
 Among the 26 bronchial wash cytology ,11 cases of SCC diagnosed   
were correlated with the   42.30%of biopsies.  Most of sputum cytology were 
positive for squamous cell carcinomas. 
 
 Among 78 cases of squamous cell carcinoma, local metastasis were seen 
in 11 cases (14.10 %), 9 cases(11.53%) showed regional metastasis and 8 
cases (10.25%) showed distant metastasis . 
 
ADENOCARCINOMA: 
 In this study, adenocarcinoma constitutes the second most common type 
of NSCLC next to SCC . The diagnosis of adenocarcinoma was made on the 
basis of  glandular structure and mucin production. 
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 Among the total cases o f 151 cases, 29.1% (n=44) cases  comes under 
this category. The predominant age group was  51 to 60 years with the mean 
age of  57.02 years.15cases were noted in this category with the percentage of 
34%. No cases were reported under the age of 30 years. Out of 44 cases 
,59%(n=26)  were males and 40.9% (n=18)  were   females with the male to 
female  ratio of 1.44:1. 
 
 Out of 44 cases of adenocarcinoma 36.36% of cases were associated 
with history of smoking.Several studies concluded that the most common 
cause of lung cancer in both men and women was smoking of tobacco 
products. 
 
 Bain et al(161)found that the incidence of lung cancer among the non 
smokers,more common in men than women.This observation was in 
concurrence with this study. American cancer society have reported that 
currently the incidence of lung cancer in females is nearly equal to that of 
males.(162) Out of  these 44 cases of adenocarcinoma 36.36% of cases were 
associated with history of smoking. Several studies concluded that the most 
commom cause of lung cancer in both men and women  are due to smoking of 
tobacco products . 
 
 Most of the adenocarcinoma were seen in right upper lobe 25%(n=11) 
of cases, followed by  left upper lobe constitutes 18.18% (n= 8) cases.(159) 
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Right lung was most commonly involved than the left which is in concurrence 
with the study done by Vivekanand N et al in which  cancers of right lung  
(56.6%) is more common than the cancers of  left lung (43.30%) in a ratio of 
1.3:1,respectively. Most common radiologic finding of adenocarcinoma was 
found to be peripheral mass and opacity.(160) 
 
 Among these 44 cases of adenocarcinoma, 9 cases(20.45%) were found 
with local metastasis, 5cases(11.36%) with regional metastasis and 10 cases 
(22.72%)  with distant metastasis. in this study ,the metastasis were found to 
be more common with adeno carcinoma  than  SCC. This  is inconcurrence 
with the study done by collins  LG et al and Alberg  AJ  et al.(163,164) 
 
 With fibroptic bronchoscopic findings most of the adenocarcinomas are 
presented with endobronchial  growth. Conflictingly few cases which were 
normal /inflammed mucosa on FOB are reported as malignancy. It is  
comparable with  to  study by Schreiber G et al  which says  few of the 
lesions had no evidence of growth (or) mucosal abnormalities by FOB were  
reported as malignant. 
 
 Mixed subtype(38.6%) of ADC  when classified  based on WHO2004 
classification outnumbered other subtypes in the order of solid type (25%), 
acinar type (18.8%), papillary and bronchoalveolar subtypes each constituting 
9%.  though its the predomonant type  the percentage reported was lower  
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compared to the study done by Akihiko yoshizawa et al(165), where it found 95 
% of the patients classified into mixed group. 
 
 When  adenocarcinomas of this study were subtyped  based on patterns 
in accordance with the new  IASLC/ATS/ERS classification ,  solid type 
(30.50%) predominates  followed by acinar type (20.33%),  papillary type 
(10.16%), lepidic pattern (8.4%) and micropapillary pattern(3.38%) . 
In this study, Major differences identified  between WHO and IASLC 
classification includes , 
 
 One case of large cell carcinoma  reported according to WHO 
classification  was termed as NSCLC -NOS in the newer classification as the 
diagnosis of large cell carcinoma can be possible only with resected 
specimens.  large cell carcinoma diagnosis is possible only with resected 
specimens as it is a diagnosis by exclusion Scagliotti G et al(175) and Travis 
WD et al.(113)                                  
 
 One case of sarcomatoid carcinoma   diagnosed based on  WHO 
classification is classified under NSCLC-NOS  in the new classification as 
diagnosis of sarcomatoid carcinoma  cannot be made in small biopsies  
because there is difficulty in assessing the mixed patterns. Diagnosis of 
sarcomatoid carcinoma is made by presence of atleast 10% of giant and/or 
spindle cells and it is possible to assess only in resected specimens. 
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 With 38.6%  of the cases were subclassified into mixed subtype ,the 
2004 WHO classification has not provide any prognostic significance. (165,166). 
 
 According to IASLC classification , the mixed type was further  
subtyped based on the presence of predominant  pattern as acinar (46.15%), 
papillary (19.23%), solid (23.07%), lepidic (3.84%)  and 
micropapillary(7.69%). Among these  solid and micropapillary type indicates 
poor prognosis. Thus new classification on contrast to WHO 2004 
classification helps to prognosticate the specific subtype. 
 
 According to WHO classification Bronchoalveolar  carcinoma  
constitutes 9% of  adenocarcinomas. The term bronchoalveolar carcinoma  is  
used for  spectrum of  adeno carcinoma  tumours in resected specimens which 
have 100% to 15-20% of  5 year survival rate.  But new IASLC classification 
does not include the term bronchoalveolar carcinoma. Instead  it classifies 
previous  Non- Mucinous  BAC as Adenocarcinoma with lepidic pattern  
which has favourable outcome ( in this study it constitutes about 11.62% of 
cases) and Mucinous BAC   as mucinous adenocarcinoma which has poor 
prognosis. 
 
 In this study micropapillary adenocarcinoma constitutes 4.65% ,which is 
not included in WHO classification but included in IASLC classification 
which have poor prognosis. 
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 Kazunori et al(167), observed that the micropapillary pattern is a distinct 
variant in lung adenocarcinoma with prognostic significance. On pathological 
diagnosis this variant should be diagnosed carefully. Prognosis is poor even  in 
very early stage for the micropapillary variant .  Miyoshi T,Satoh Y et  al(168), 
also found that the presence of micropapillary pattern have a prognostic value . 
In addition it was observed  that micropapillary pattern  may be associated 
with invasion into lymphatic system and nodal metastasis and the expression 
of surfactant apoprotein A in a micropapillary area attributes to poor prognosis 
in small size adenocarcinoma of lung. 
 
 Several studies have demonstrated  the prognostic significance of new 
IASLC/ATS/ERS classification. 
 
 Morphologic diagnosis always  forms the basis of diagnosis and is 
further supplemented  by  immuno histochemical markers. In this study, the 
panel of AB/PAS, TTF-1 and p40 were used in 50 cases of poorly 
differentiated NSCLCs. Alcian blue-PAS positive in (n=20) 40% of 
cases.TTF-1 was positive in (n=25) 50% of cases and p40 was positive 
in(n=21)  42%  0f cases.  Both TTF-1 and p40 were negative in (n=3)  6% of 
cases. 
 
 In this study , among the 10 cases classified by WHO  as poorly 
differentiated adenocarcinoma , AB/PAS showed positivity in 70% of  cases 
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and TTF-1 showed positivity in 80% of cases. Sensitivity of  TTF-1 was found 
to be 100%,and specificity was found to be 91%. 
 
 According to  Kennedy et al.,(169)  Mucin stains are valuable markers, 
but it shows variable sensitivity and specificity for adenocarcinoma.  It is one 
classical characteristic feature of pulmonary adenocarcinoma ,but still  it is not 
seen in all  cases . In addition ,study by Kennedy et al,(169) found that by the 
use of PAS staining method the percentage of positive (90%) is slightly less  
when compared to the higher percentage of positivity (93%) obtained by the 
combined Alcian blue –PAS  method. Hence the combination staining method 
using Alcian blue –PAS seems to give more satisfactory results.  
 
 In this study the TTF-1 positivity were noted in 96.15% of 
adenocarcinoma.   According to the study by Stenhouse G et al(170), TTF-1 as 
a marker for adenocarcinoma was found to have specificity  of 97-100%, but 
the sensitivity rate was low at 54-75%. It also showed that in subtyping of 
tumours in the undifferentiated NSCLC category they found that the 
expression of   TTF1 marker was present  in 70 to 85% of lung 
adenocarcinomas .  On an average the positivity for TTF1 marker in 
morphologically diagnosable adenocarcinomas ranges from 60 to 92%. 
 
 Kaufmann et al(171),concluded that 75% of nonmucinous 
adenocarcinomas demonstrated TTF-1 positivity. whereas mucinous 
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adenocarcinoma showed positivity only in 10%. Therefore the combined usage 
of TTF-1 and mucin stain AB/PAS has more significant value in the diagnostic 
panel. 
 
 In our  study one case of poorly differentiated adenocarcinoma was 
negative for TTF-1 stain , but, on the other hand  it showed positivity for 
AB/PAS stain . Hence in correlation with Kauffman et al (171), owing to the 
positivity of mucin stain in this study it is diagnosed as fovouring 
adenocarcinoma 
 
 In the present study  p40 showed positivity in all the 10 cases classified 
by WHO as poorly differentiated squamous cell carcinoma.  
 
 According to Wei zhao et al., (172)p40 is considered to be the best  
marker  in differentiating SCC and adenocarcinoma. p40 has  sensitivity of 
100%,and  specificity of 100%. Present study is in accordance with  this view. 
In the recent study by Bishop et al , in terms of sensitivity for  SCC ,it was 
found to be equal for the two markers p40 and p63, but  in terms of  specificity 
p40 proved to be superior. Though p63 is the marker for SCC it can show 
positivity in some cases of adenocarcinoma or an unsuspected lymphoma. so 
p40 is the ideal marker   in the diagnosis of SCC  of lung. Another study  by 
Pelosi G et al,  also strongly recommend p40 as a reliable and more superior 
marker for SCC. 
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 Hence the use of p40 in conjunction with TTF-1 was justified to be a 
promising diagnostic tool in the routine practise for subtyping of  NSCLC. 
 
 Giuseppe Pelosi et al(173), also emphasized  the application of two 
marker panel which comprises of p40 and TTF-1 on small biopsy or cell block 
samples was considered more effective and reliable in correctly subtyping a 
vast majority of lung cancers. Similar findings were recorded in yet another 
study by “Brown and colleagues et al’’(174) who concluded that the use of 
TTF-1/p40 cocktail on small biopsy for differentiating  lung SCC  and ADC  
was very effective. The added benefit is that we can employ this cocktail on a 
single slide.    
 
 In this study, among the 151 cases of NSCLCs,  30 cases  belonged to  
not otherwise specified (NOS) constituting 19.86% of the total. But with the 
use of Mucin stains, and IHC markers TTF-1 and p40 , it was minimised to 
1.98% 
 
 Also in this study, when  intrepreted according to the new 
classififcation, among these 30 cases of undifferentiated non small cell 
carcinoma (NOS) group, were subtyped  using special stains and IHC markers 
into 
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  Favouring adenocarcinoma  15 cases (50 %), 
  Favouring squamous cell carcinoma 11cases (36.66%),  
  Possible adenosquamous carcinoma was 1 case( 3.33% )and 
  Unsubtyped were 10%(n=3). 
 
Diagnostic algorithm for classification on NSCLC in small biopsy: 
 
 
 
 
 
Summary 
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SUMMARY 
 
 Among the total number of  392 lung specimens received in the institute 
of pathology ,Madras Medical College during the study period of july 
2013 to june 2014, 323 were small biopsy specimens and among them 
183  were reported as malignancy with  relative percentage of  56.65%. 
 Non small cell lung carcinoma (82.51%)  vastly outnumbered the small 
cell lung carcinoma (8.60%) in our study. 
 The distribution of SCC and ADC was 51.65% and 29.1% respectively. 
Thus squamous cell carcinomas are more frequent than adenocarcinoma.  
NSCLC-NOS  accounted for 19.8%. 
 Among the 50 cases of poorly differentiated NSCLCs, Alcian blue-PAS 
was positive in  40% of cases. TTF-1 was positive in  50% of cases and 
p40 was positive in 42%  of cases. Both TTF-1 and p40 were positive in  
2% of  the cases. Both TTF-1 and p40 were negative in  6% of cases. 
 One case of poorly differentiated adenocarcinoma was negative for TTF-1 
stain , but  on the other hand,  it showed positivity for AB/PAS stain .  
Owing to the positivity of mucin stain in this case it was diagnosed as 
NSCLC favouring adenocarcinoma.  
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 Undifferentiated group not otherwise specified constituting 19.86% of the 
total of 151 cases. But with the use of Mucin stain, and IHC markers 
TTF-1 and p40 , it was minimised to  3%. 
 According to IASLC s new classififcation, undifferentiated non small cell 
carcinoma (NOS) group, were subtyped  using special stains and IHC 
markers into favouring adenocarcinoma 50%, favouring squamous cell 
carcinoma 36.66%,possible adenosquamous carcinoma 3.33%  and 
unsubtyped were 10% 
 38.6%  of cases of Adenocarcinoma were subclassified into mixed 
subtype , based on  2004 WHO classification  
 According to IASLC classification , the mixed type was further  subtyped 
based on the presence of pattern as acinar (46.15%),  papillary (19.23%), 
solid (23.07%), lepidic (3.84%)  and micropapillary(7.69%). Among 
these  solid and micropapillary type indicates poor prognosis. Thus new 
classificationof IASC,  in contrast to WHO 2004 classification helps to 
prognosticate the specific subtype. 
 According to WHO classification Bronchoalveolar  carcinoma  
constitutes 9% of  adenocarcinomas. But the term bronchoalveolar 
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carcinoma  is  no longer used. As per IASC classification, it is termed as 
Adenocarcinoma with lepidic pattern. 
 In this study micropapillary adenocarcinoma constitutes 4.65% ,which is 
not included in WHO classification but included in IASLC classification 
which have poor prognosis. 
 
  
 
 
 
 
Conclusion 
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CONCLUSION 
 International classification for lung cancer needs a special mention is 
that it is the first ever engineered classification for lung malignancies in 
small  biopsy /cytology.   
 According to this study we conclude that multidisciplinary International 
Classification For  Lung Cancer is superior to 2004 WHO classification  
in terms of  diagnostic, therapeutic and prognostic implications. 
 As a surgical pathologist ,our role does not end in classifying lung 
malignancies as SCLC and NSCLC but has to be subtyped using special 
stains and IHC markers. Alcian blue-PAS and IHC markers like TTF-1 
and P40 are found to be extremely efficient  and useful markers. 
 Furthermore ,in this  era of  targeted therapy, basic histopathological 
diagnosis per se is not enough but further histological subtyping as well 
as molecular testing are of paramount importance, as these are the key 
factors determining the treatment options. 
 Thus the surgical pathologist can be considered as the sole guardian of 
these small biopsy specimens-The very precious yet limited resource 
from which one needs to maximise the diagnostic yield. 
 
 
 
 
Annexures 
 
 
 
ANNEXURE-I 
PROFORMA 
Case number             :                                                  Name      : 
HPE number             :                                                  Age         :  
IP number                 :                                                  Sex         : 
Clinical diagnosis     :  
Complaint                 : 
Radioimaging           : 
FOB findings           : 
Site of lesion             : Right upper lobe/middle lobe/lower lobe 
                                    Left upper lobe/hilum/lower lobe 
Specimen                  :CT guided biopsy/Bronchial biopsy/USG guided  
                                   biopsy/Open biopsy 
MICROSCOPY       : Histological diagnosis according to WHO classification 
Special  stain            : 
Alcian blue/PAS 
IHC 
             TTF-1         :  Positive / Negative               
             p40             : Positive / Negative    
DIAGNOSIS          :According  to IASLC/ATS/ERS classification 
            
  
  
                                                ANNEXURE:III 
PROPOSED IASLC/ATS/ERS CLASSIFICATION FOR SMALL 
BIOPSIES/CYTOLOGY 
2004 WHO Classification SMALL BIOPSY/CYTOLOGY: 
IASLC/ATS/ERS 
ADENOCARCINOMA       
Mixed subtype 
Acinar 
Papillary 
Solid 
Morphologic Adenocarcinoma pattern 
clearly presents:Adenocarcinoma, 
describe identifiable patterns present 
(including micropapillary pattern not 
included in 2004 WHO classification) 
No 2004 WHO counterpart – most 
will be solid adenocarcinomas 
Morphologic adenocarcinoma patterns 
not present (supported by special 
stains): Non-small cell carcinoma, 
favor adenocarcinoma 
Bronchioloalveolar carcinoma        
(nonmucinous) 
Adenocarcinoma with lepidic pattern 
(if pure, add note: an invasive 
component cannot be excluded) 
 Bronchioloalveolar carcinoma       
(mucinous) 
Mucinous adenocarcinoma (describe 
patterns present) 
 Fetal Adenocarcinoma with Fetal pattern 
 Mucinous (colloid) Adenocarcinoma with colloidal 
pattern 
Signet Ring  Adenocarcinoma with (describe 
patterns present) and signet ring 
features 
Clear cell Adenocarcinoma with (describe 
patterns present) and clear cell 
features 
SQUAMOUS CELL CARCINOMA        
Papillary         
Clear cell         
Small cell        
Basaloid 
Morphologic squamous cell pattern 
clearly presents: 
Squamous cell carcinoma 
No 2004 WHO counterpart Morphologic squamous cell patterns 
not present (supported by stains): 
Non-small cell carcinoma, favor 
squamous cell carcinoma 
SMALL CELL CARCINOMA 
 
Small cell carcinoma 
LARGE CELL CARCINOMA Non-small cell carcinoma, not 
otherwise specified (NOS) 
Large cell neuroendocrine carcinoma          
(LCNEC) 
Non-small cell carcinoma with 
neuroendocrine (NE) morphology 
(positive NE markers), possible 
LCNE 
Large cell carcinoma with N 
morphology(LCNEM) 
             
Non-small cell carcinoma with NE 
morphology (negative NE markers) – 
see comment  
Comment: This is a non-small cell 
carcinoma where LCNEC is 
suspected, but stains failed to 
demonstrate NE differentiation. 
ADENOSQUAMOUS 
CARCINOMA 
Morphologic squamous cell and 
adenocarcinoma patterns present: 
Non-small cell carcinoma, NOS, 
(comment that glandular and 
squamous components are present 
No counterpart in 2004 WHO 
classification 
Morphologic squamous cell or 
adenocarcinoma patterns present and 
stains are conflicting (TTF1 and p63 
positive) or suggest the other pattern 
is also present Non-small cell 
carcinoma, NOS, comment that 
glandular and squamous 
differentiation seen by IHC) Comment 
(for either setting): this could 
represent adenosquamous carcinoma. 
Sarcomatoid carcinoma Poorly differentiated NSCLC with 
spindle and/or giant cell carcinoma 
(mention if adenocarcinoma or 
squamous carcinoma are present) 
 
 
                                                 
 
 
 
 
                                           ANNEXURE:IV 
IASLC/ATS/ERS CLASSIFICATION OF LUNG ADENOCARCINOMA 
IN RESECTION SPECIMENS 
PREINVASIVE  LESIONS 
A typical adenomatous hyperplasia 
Adenocarcinoma in situ (≤3 cm formerly BAC)  
              -Nonmucinous   
              -Mucinous       
              -Mixed Mucinous/Non-Mucinous 
MINIMALLY INVASIVE ADENOCARCINOMA (≤3 cm lepidic 
predominant tumor with ≤5 mm invasion) 
              -Non mucinous       
              -Mucinous     
              -Mixed Mucinous/Non-Mucinous 
INVASIVE ADENOCARCINOMA  
Lepidic predominant (formerly non-mucinous BAC pattern, with >5 mm 
invasion)  
Acinar predominant  
Papillary predominant  
Micropapillary predominant  
Solid predominant with mucin production 
VARIANTS OF INVASIVE ADENOCARCINOMA   
Invasive mucinous adenocarcinoma (formerly mucinous BAC)  
Colloid  Fetal (low and high grade)  
Enteric 
ANNEXURE-V 
 
Special staining (PAS/ALCIAN BLUE) procedure: 
1. Bring sections to distilled water. 
2. Stain with Alcian blue 15 mins. 
3. Wash well in running tap water  for 2 mins. 
4. Rinse in distilled water. 
5. Treat with periodic acid 5 mins. 
6. Wash well in distilled water. 
7. Stain with Schiff's reagent  for 10 mins. 
8. Wash well in running tap water for  5 mins. 
9. Stain nuclei with haematoxylin  for 1 min. 
10. Wash in running tap water  for 2 mins. 
11. Differentiate with acid alcohol. 
12. Wash and blue nuclei in Scott’s tap water. 
13. Wash in water. 
14. Dehydrate, clear and mount. 
 
Results will be interpreted as 
 Neutral mucins  will appear in Magenta 
 Acidic mucins in  Blue 
 Nuclei  in  Deep blue 
 Mixtures of above  in Blue/purple 
  
ANNEXURE-VI 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 μ were cut from formalin fixed paraffin 
embedded tissue samples and transferred to gelatin-chrome alum coated 
slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were  deparaffinised in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes for 2 
changes. 
5. Then the sections were  washed with  tap water for 10 minutes. 
6. The slides are  then immersed in distilled water  upto  5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. This 
step unmasks the antigenic determinants of fixed tissue sections. 
2. The slides were then cooled to room temperature for 20 minutes and 
washed with tap water for 5 minutes. 
3. The slides were then rinsed with  distilled water for 5 minutes. 
4. then the slides were washed with appropriate wash buffer (phosphate 
buffer) for 5 minutes x 2 changes. 
5. Peroxidase block was then applied  for 10 minutes. 
6. The slides then were washed in phosphate buffer for 5 minutes x 2 
changes. 
7. Sections were covered with protein block for 5 minutes. 
 
Antibody application: 
1. The sections were drained (without washing) and appropriate primary 
antibody is  applied  and incubated for 30 minutes. 
2. The slides were washed in  the phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with Primary antibody amplifier for 10 
minutes. 
4. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with HRP micropolymer Quanto for 10 
minutes. 
6. The slides were washed in  the phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB Quanto 
chromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. wash the slides then in distilled water for 2 minutes. 
4. counterstain  the section with Hematoxylin  for 2 seconds. 
5. wash the slides in running tap water for 5 minutes. 
6. air dry the slides, cleared with xylene and mounted with DPX. 
 
Alternate methods of antigen retrieval 
 Pressure cooker antigen retrieval 
 Microwave and trypsin antigen retrieval 
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                                    KEY TO MASTER CHART 
 
HPE NO:Histopathological examination number 
 M            : Male 
 F              : Female 
Site  
1 : Right upper lobe 
2 : Right middle lobe 
3 : Right lower lobe 
4 : Left upper lobe 
5 : Left lower lobe 
6 : Left hilum 
 
Smoking  
Y             :Yes 
N             :No 
C/F          :Clinical Features 
1  : Cough 
2   :  Hemoptysis 
3   :  Breathlessness 
4   : Chest pain 
5   : Weight loss 
R/F            : Radiological features 
M              : Mass 
H               : Hilar mass 
ME      : Mediastinal invasion 
B/L  : Bilateral lung involvement 
C  : Chest invasion 
B            : Brain metastasis 
PE         : Pleural effusion 
CN       : Cervical node metastasis 
MNI      : Ipsilateral mediastinal lymphnode involvement 
MNC     : Contralateral mediastinal lymphnode involvement 
MXN   : Multiple nodules 
O         : Opacity 
F         : Fibrosis 
E         : Emphysematous changes 
A               : Adrenal metastasis 
CON         : Consolidation 
CAV         : Cavity 
LI             : Liver metastasis 
SCN         : Supraclavicular lymphnode metastasis 
RIB          : Rib erosion 
V              : Vertebral involvement 
FOB        : Fibroptic bronchoscopy 
N             : Normal mucosa 
NB           : Narrowed bronchus 
M             : Mass 
P              : Polypoidal lesion 
IM           : Inflamed mucosa 
SP            : Sputum 
BW          : Bronchial wash 
PF           : Pleural fluid 
NEG       : Negative 
POS       : Positive 
 
Specimen: 
 1 : Computed tomogram guided biopsy 
 2 : Bronchial biopsy 
 3 : Transbronchial bipsy 
 4 : Ultrasonogram guided biopsy 
 
HPE diagnosis : Histipathological examination diagnosis 
A PD   : Adenocarcinoma poorly differentiated 
AS    : Adenocarcinoma solid type 
AA   : Adenocarcinoma acinar tyype 
AB   : Adenocarcinoma bronchoalveolar type 
AM   : Adenocarcinoma mixed type 
AP   : Adenocarcinoma papillary type 
S      : Squamous cell carcinoma 
S PD   : Squamous cell carcinoma poorly differentiated 
N PD   : Non small cell carcinoma poorly differentiated 
AB/PAS  : Alcian blue/periodic acid Schiff 
TTF-1  : Thyroid transcription factor 
P   : Positive 
N   : Negative 
IASLC/ATS/ERS : International association for the study of lung  
    cancer/american thoracic society/European  
    respiratory  society 
AMP   : Adenocarcinoma micropapillary type 
AL   : Adenocarcinoma lepidic type1 
